 
Official Title:  A Pi[INVESTIGATOR_362189] -Label Study of the Efficacy and Safety of Imetelstat (GRN163L) 
in Myelofibrosis and Other Myeloid Malignancies  
Study ID: [REMOVED] 
 
Document  Date :  
Clinical Study Protocol : 05 October  2015 
 
    
 
 
 
Page 1 of 90CLINICAL STUDY PROTO COL
TITLE: A Pi[INVESTIGATOR_362189]- Label Study  of the Efficacy  and Safety  of 
Imetelstat (GRN163L ) in My elofibrosis and other My eloid 
Malignancies
PROTOCOL NUMBER: CP14B019 (formerly  MC1285)
IND: [ADDRESS_451297] NUMBER: N/A
STUDY DRUG: JNJ-63935937 ( Imetelstat Sodium for I njection ) (formerly  
GRN163L  for I njection)
SPONSOR: Janssen Research & Development
Document History (Effective Date)
Activation October 26, [ADDRESS_451298] 29, 2013
Mayo Add5 December 4, 2013
Mayo Add6 Protocol changes not approved
Mayo Add7 December 30, 2013
Mayo Add8 February  18, 2014
Mayo Add 9 March 3, 2014
Mayo Add 10 April 7, 2014
Geron Document History
Amendment 11(Protocol Final ization Date)
July 31, 2014
Janssen Research & 
Development Document 
History(Approval Date)
Amendment 12 21January 2015
Amendment 13 5October 2015
EDMS number: EDMS
-ERI-98370922, 2.0
Protocol CP14B019, Amendment 13
Page 2of 90   
PROTOCOL FINALIZATIO N SIGNATURE [CONTACT_362262]: A Pi[INVESTIGATOR_362189]- Label Study  of the Efficacy  and Safety  of 
Imetelstat (GRN163L ) in My elofibrosis and other My eloid 
Malignancies
PROTOCOL NUMBER: CP14B019 (formerly  MC1285)
IND: [ADDRESS_451299] NUMBER: N/A
STUDY DRUG: Imetelstat Sodium for Injection (GRN163L  for I njection)
SPONSOR: Janssen Research & Development
Document History (Effective Date)
Activation October 26, [ADDRESS_451300] 29, 2013
Mayo Add5 December 4, 2013
Mayo Add6 Protocol changes not approved
Mayo Add7 December 30, 2013
Mayo Add8 February  18, 2014
Mayo Add 9 March 3, 2014
Mayo Add 10 April 7, 2014
Geron Document History
Amendment 11(Protocol Finalization Date)
July 31, 2014
Janssen Research & 
Development History(Approval Date)
Amendment 12 21 January
 2015
Amendment 13 5October 2015
Protocol CP14B019, Amendment 13
Page 3of 90  
TABLE OF CONTENTS
Protocol Finalization Signature [CONTACT_3490] ...............................................................................................2
PROTOCOL  AMENDMENTS .....................................................................................................18
1. BACKGROUND ........................................................................................................22
1.1. Myelofibrosis ..............................................................................................................22
1.2. Telomeres and Telomerase I nhibition ........................................................................22
1.3. Imetelstat .....................................................................................................................23
1.3.1. Noncli nical Pharmacology ..........................................................................................23
[IP_ADDRESS]. Efficacy  Studies ..........................................................................................................23
[IP_ADDRESS]. Effects on Cancer Stem Cells .....................................................................................23
1.3.2. Nonclinical Safety  Studies ..........................................................................................24
1.3.3.
Clinical Experience with I metelstat ............................................................................25
1.3.4. Safety  Experience .......................................................................................................29
[IP_ADDRESS]. Hematologic Events ................................ ................................ ................................ ....29
[IP_ADDRESS]. Coagulation Changes ..................................................................................................30
[IP_ADDRESS]. Infections ....................................................................................................................30
[IP_ADDRESS]. Hepatobiliary  Events ................................ ................................ ................................ ...30
[IP_ADDRESS]. Infusion Reactions ................................ ................................ ................................ ......32
[IP_ADDRESS]. Gastrointestinal Events ................................ ................................ ............................... 32
[IP_ADDRESS]. Constitutional Sy mptoms ................................ ................................ ............................ [ADDRESS_451301] Schedule For Hepatic Safety  Monitoring And Follow Up After 
Discontinuing I metelstat ................................ ................................ ............................. 46
Protocol CP14B019, Amendment 13
Page 4of 905. GROUPI [INVESTIGATOR_362190] ................................ ................................ ............................. 47
6. REGI STRATI ON/RANDOMI ZATION PROCEDURES ..........................................47
6.1. Registration Procedures ..............................................................................................47
7. PROTOCOL  TREATMENT ......................................................................................48
7.1. Treatment Schedule ....................................................................................................48
7.1.1. Imetelstat Treatment ...................................................................................................48
[IP_ADDRESS]. Arm A Treatment Schedule ........................................................................................49
[IP_ADDRESS]. Arm B Treatment Schedule ........................................................................................49
[IP_ADDRESS]. Arms C and D Treatment Schedule ............................................................................50
[IP_ADDRESS]. Arms E and G Treatment Schedule ............................................................................50
[IP_ADDRESS]. Arm F Treatment Schedule .........................................................................................51
7.2. Pre-Medication ...........................................................................................................52
8. DOSAGE MODI FICATION BASED ON ADVERSE EVE
NTS ..............................53
8.1. Retreatment Criteria ....................................................................................................53
8.2. Dose Reduction ................................ ................................ ................................ ........... 53
8.2.1. Hepatoxicity ................................ ................................ ................................ ................ 55
8.3. Infusion Reaction ................................ ................................ ................................ ........ 56
9. ANCI LLARY TREATMENT/ SUPPORTI VE CARE ................................ ............... 57
10. ADVERSE EVENT (AE) R EPORTI NG AND MONI TORI NG...............................57
10.1. Safety  Parameters and Definitions ..............................................................................57
10.1.1. Adverse Event .............................................................................................................58
10.1.2. Serious Adverse Event ................................ ................................ ................................ 58
10.2. Methods and Timing for Capturing and Assessing Safety  Parameters .......................59
10.2.1. Adverse Event Reporting Period ................................................................................59
10.2.2. Eliciting Adverse Events ................................ ................................ ............................ 60
10.2.3. Assessment of Severity  and Causality  of Adver se Events ................................ .......... 60
10.3. Procedures for Recording Adverse Events .................................................................61
10.3.1. Recording Adverse Events on the eCRF ....................................................................61
[IP_ADDRESS]. Diagnosis Versus Signs and Sy mptoms ......................................................................61
[IP_ADDRESS]. Adverse Events Occurring Secondary  to Other Events ................................ .............. 61
[IP_ADDRESS]. Persistent or Recurrent Adverse Events ......................................................................62
[IP_ADDRESS]. Abnormal L aboratory  Values ......................................................................................62
[IP_ADDRESS]. Deaths ................................ ................................ ................................ ......................... 62
Protocol CP14B019, Amendment 13
Page 5of 9010.3.1.6. Preexisting Medical Conditions ..................................................................................62
[IP_ADDRESS]. Worsening of MF ........................................................................................................63
[IP_ADDRESS]. Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_059], or Surgery .............................................63
[IP_ADDRESS]. Pregnancy ....................................................................................................................63
[IP_ADDRESS]. Hepatic Adverse Events and Abnormal L
iver Biochemistries ...................................63
10.4. Expedited Reporting Requirements for Serious Adverse Events ...............................64
10.4.1. Reporting Requirements for Fatal/L ife Threatening SAEs Related to 
Investigational Product ...............................................................................................[ADDRESS_451302]-Study  Adverse Events .........................................................................................65
11. TREATMENT EVAL UATI ON.................................................................................66
11.1. Myelofibrosis ..............................................................................................................66
11.2. MDS ............................................................................................................................68
12. DESCRI PTIVE FACTORS ................................ ................................ ........................ 70
13. TREATMENT/FOLLOW –UP DECI SION AT EVALU ATION OF 
PATI ENT ....................................................................................................................70
14. BODY FLUID BIOSPECIM ENS ...............................................................................71
15. DRUG I NFORMATI ON................................ ................................ ............................ 71
15.1. Imetelstat (GRN163L ) ................................ ................................ ................................ 71
15.1.1. Background .................................................................................................................71
71
72
15.1.4. Administration ................................ ................................ ................................ ............ 72
15.1.5. Pharmacokinetic information: ....................................................................................72
15.1.6. Potential Drug I nteractions .........................................................................................73
15.1.7. Safety  Experience .......................................................................................................73
15.1.8. Drug Procurement ................................ ................................ ................................ .......73
15.1.9. Nursing Guidelines ................................ ................................ ................................ .....73
16. STATI STICAL  CONSI DERATI ONS AND METHODOLO GY.............................. 74
16.1. Statistical Design (To Be Evaluated I ndependently  in Each Arm) .............................74
16.2. Analy sis Plan ................................ ................................ ................................ .............. 76
16.3. Primary  Outcome Analy ses(to be evaluated in each arm independently ) .................. 77

Protocol CP14B019, Amendment 13
Page 6of 9016.4. Secondary  Outcome Analy ses (to Be Evaluated in Each Arm I ndependently ) .......... 77
16.4.1. Adverse Events ...........................................................................................................77
16.4.2.
Spleen Response .........................................................................................................77
16.4.3. Transfusion
-Independence ..........................................................................................77
16.4.4.
Durability  of Response ...............................................................................................78
16.5. Exploratory  Outcomes (to Be Evaluated in Each Arm I ndependently )
......................[ADDRESS_451303] and I mmature Cell 
Count ................................ ................................ ................................ ........................... 78
16.6. Over Accrual ...............................................................................................................78
16.7. Data and Safety  Monitoring ........................................................................................78
16.8. Adverse Event Stoppi[INVESTIGATOR_1869] (to Be Evaluated in Each Arm I ndependently )
.........79
16.9. Inclusion of Women and Minorities
...........................................................................79
17. PATHOL OGY CONSI
DERAT IONS/TI SSUE BI OSPECI MENS ............................ 81
17.1. Tissue and Biospecimen Submission..........................................................................81
17.2. Initial a nd Respo nse Evaluati onMaterials ................................ ................................ .81
18. REFERENCES ................................ ................................ ................................ ........... 83
APPENDI X A. DIPSS-PLUS RI SK CATEGORI ESIN MYEL OFIBROSIS. ........................... 85
APPENDI X B. WORL D HEALTH ORGANI ZATION (WHO) DI AGNOSTIC  
CRITERI A FOR POL YCYTHEMI A VERA, ESSENTI AL 
THRO MBOCYTHEMI A AND PRI MARY MYEL OFIBROSIS3...................[ADDRESS_451304] ASMS RESEARCH AN D 
TREATMENT (I WG-MRT) RECOMMENDED CRI TERI A FOR 
POST -POLYCYTHEMI A VERA AND POST
-ESSENTI AL 
THROMBOCYTHEMI A MYEL OFIBROSIS ..................................................[ADDRESS_451305] OF TABLES
Table 1: Phase I  Clinical Trials with I metelstat ........................................................................27
Table 2: Phase I I Trials with I metelstat ....................................................................................28
Table 3: Test Schedule:  Core Phase = Cy cle 1 
–Cycle 9; Extension Phase = Cy cle 10 
and Bey ond .................................................................................................................43
Table 4: Test Schedule for Hepatic Safety  Monitoring And Follow Up After 
Discontinuing I metelstat ................................ ................................ ............................. 46
Table 5: Arms E and G Dosing if Criteria met = Yes ...............................................................51
Table 6: Arm F Dosing if Criteria met = Yes ...........................................................................51
Table 7: Arm F Dosing if Criteria met = No: Cy cles 3 and 4 ...................................................52
Table 8: Criteria met = No: Cy cles 5 and bey ond
.....................................................................52
Table 9: Dose Reductions .........................................................................................................53
Table 10: Dose Levels (Based on Adverse Events in Table 9)
................................ ................... 54
Table 11: ALERT : Serious Adverse Event (SAE) reporting may  be required for some 
adverse events (See Section 10) ..................................................................................54
Table 12: Guidelines for Managing I nfusion Reactions ................................ ............................. 56
Table 13: Adverse Event Grade (Severity ) Scale ........................................................................60
Table 14: Causal Attribution Guidance ......................................................................................61
Table 15: Revised I nternational Working Group for My eloproliferative Neoplasms 
Research and Treatment (I WG-MRT) and European LeukemiaNet (ELN) 
response criteria for my elofibrosis. .............................................................................66
Table 16: Definiti
on of Disease Response in MDS: ...................................................................68
Table 17: Proposed Modified I nternational Working Group Response Criteria for 
Hematologic I mprovement .........................................................................................69
Table 18:
Expected Sizes of Racial by  [CONTACT_362217] ................................ .............................. 80
Table 19: Summary  Table of Tissue Biospecimens for this Protocol ................................ ......... [ADDRESS_451306] OF FIGURES
Figure 1: Schema – Arm A ..........................................................................................................9
Figure 2: Schema 
–Arm B ................................ ................................ ................................ ......... 10
Figure 3: Schema – Arms C and D ............................................................................................11
Figure 4: Schema 
–Arm E ................................ ................................ ................................ ......... 12
Figure 5: Schema – Arm F ................................ ................................ ................................ ......... 14
Figure 6: Schema – Arm G ................................ ................................ ................................ ........ 16
Protocol CP14B019, Amendment 13
Page 8of 90Figure 7: Inhibition of Telomerase Activity  by [CONTACT_362218] a DU145 Tumor Flank 
Model and L iver Telomerase I nhibition Model ..........................................................35
Figure 8: Imetelstat (GRN163L ) Tissue Distribution in Rats ....................................................36
Figure 9: Imetelstat Weekly  AUC infin Patients and in Xenograft Mice ....................................37
Protocol CP14B019, Amendment 13
Page 9of 90Note: All Study Arms (A, B, C, D, E, F, and G) are now permanently closed to accrual
Figure 1: Schema –Arm A
(Note: Arm A permanently  closed to accrual)
Ifa patient is deemed ine ligible or a cancel, please refer to Section 13for follow -
up information.
1Cycle length = 21 days .For patients who do not achieve a CR orPRby [CONTACT_5638] C ycle 6, the frequency of dosing may be 
increased and the cy cle length will be 21 -28 days. For patients whose response has plateaued for a minimum of 3 months, the 
dose frequency may be reduced , or treatment may be interrupted until relapse then restarted, and the cycle length will be the 
length of the dosing interval .  See Section 7.1.For all patients who did not experience a treatment emergent abnormality in 
liver function tests (LFTs), defined as any grade abnormality in patients with normal value at baseline or any higher grade shift 
from baseline in patients with an abnormal baseline , or value more than 2x baseline if baseline was G rade ≥ 3,or hepatic 
adverse events are present at imetelstat discontinuation, obtain LFT follow -
up until [ADDRESS_451307] 
schedule (see Section 4for details) until resolution to at least baseline grade or less than 2x baseline value if baseline was 
Grade ≥ 3for at least [ADDRESS_451308] .
3Except relapse that occurs during dose interrupti on.  These patients may restart treatment at the physician ’sdiscretion per 
Section 7.1.Registration
Cycles 1-91(Core P hase) :
IV Im etelstat
Repeat every 21 days x 9 cycles2
Event Monitoring /
Hepatic Safety Monitoring
PD at any tim e3
Unacceptable adverse events        Event
Patient r efusal                     Monitoring /
     Hepatic Safety MonitoringCycles 101and Beyond (Extension Phase) :
IV Im etelstat
Repeat every 21 days2
(see schedule of events for details)
Protocol CP14B019, Amendment 13
Page 10of 90Figure 2: Schema –Arm B
(Note:  Arm B permanently  closed to accrual)
If a patient is deemed ineligible or a cancel, please refer to Section 13for follow -
up information.
1Cycle length = 21 days . For patients who do not achieve a CR or PR by [CONTACT_42334] 6, the frequency of dosing may be 
increased and the cycle length will be 21 -28 days.  For patients whose response has plateaued for a minimum of 3 months, the 
dose frequency may be reduced, or treatment may be interrupted until relapse then restarted, and th e cycle length will be the 
length of the dosing interval .  See Section 7.1.  For all patients who did not experience a treatment emergent abnormality in 
liver function tests (LFTs), defined as any grade abnormali ty in patients with normal value at baseline or any higher grade shift 
from baseline in patients with an abnormal baseline , or value more than 2x baseline if baseline was Grade ≥3,or hepatic 
adverse events are present at imetelstat discontinuation, obtain LFT follow -up until [ADDRESS_451309] 
schedule (see Section 4for details) until resolution to at least baseline grade o r less than 2x baseline value if baseline was 
Grade ≥[ADDRESS_451310].
3Exce pt relapse that occurs during dose interruption.  These patients may restart treatment at the physician ’sdiscretion per 
Section 7.1.Registration
Induction 
Cycle 11(Core Phase) :
IV Im etels tat Days 1, 8, 15
Event Monitoring/
Hepatic Safety Monitoring
PD at any tim e3
Unacceptable adverse events              Event
Patient refusal                           Monitoring /
Hepatic Safety MonitoringMaintenance
Cycles 2-91(Core Phase):
IV Im etelstat Day 1
Repeat every 21 days2
Cycles 10 and Beyond (Extension Phase):
IV Im etelstat Day 1
Repeat every 21 days2
Protocol CP14B019, Amendment 13
Page 11of 90Figure 3: S chema –Arms C and D
(Note: Arm s
Cand D permanently  closed to accrual)
If a patient is deemed ineligible or a cancel, please refer to Section 13for follow -up information.
1Cycle length = 28 days. For all patients who did not experience a treatment emergent abnormality in liver function tests 
(LFTs), defined as any grade abnormality in patients with normal value at baseline or any higher grade shift from baseline in 
patients with an abnormal baseline , or va lue more than 2x baseline if baseline was Grade ≥ 3,or hepatic adverse events are 
present at imetelstat discontinuation, obtain LFT follow -
up until [ADDRESS_451311] schedule (see 
Section 4for details) until resolution to at least baseline grade or less than 2x baseline value if baseline was Grade ≥ [ADDRESS_451312] two cyc les, dosing might be increased to either Days 1, 3, 5 or Days 1, 3 every 2 to 
4 weeks, per physician discretion.   See Section 7.1.
3For patients whose response has plateaued for a minimum of 3 months, the dose f requenc y may be reduced , or treatment may 
be interrupted until relapse then restarted , at the physician ’sdiscretion.   See Section 7.1.
4Patients may continue to receive imetelstat study treatment for as long as they derive clinical benefit or until study end. The 
study will end when all subjects have discontinued study drug, the last patient enrolled has been treated for 5 years, or 
imetelstat is commercially available in the [LOCATION_002], whichever occurs firs t.
5Except relapse that occurs during dose interruption.  These patients may restart treatment at the physician ’sdiscretion per
Section 7.1.Registration
Cycle 1 -91(Core P hase) :
IV Im etelstat Days 1, 8, 15, 22
Repeat every 28 days2,3
Event Monitoring /
Hepatic Safet y MonitoringCycles 10 and Beyond (Extension Phase) :
IV Im etelstat Day 1, 8, 15, 22
Repeat every 28 days4,3
PD at any tim e5
Unacceptable adverse events        Event
Patient refusal              
       Monitoring /
          Hepatic Safety Monitori ng
Protocol CP14B019, Amendment 13
Page 12of 90Figure 4: Schema –Arm E
(Note: Arm E permanently closed to accrual) (myelofibrosis patients with spliceosome mutations or ring 
sideroblasts)
1Cycle length = 28 days. For all patients who did not experience a treatment emergent abnormality in liver func tion tests 
(LFTs), defined as any grade abnormality in patients with normal value at baseline or any higher grade shift from baseline in 
patients with an abnormal baseline , or value more than 2x baseline if baseline w as Grade ≥ 3,or hepatic adverse events are 
present at imetelstat discontinuation, obtain LFT follow -
up until [ADDRESS_451313] schedule (see 
Section 4for details) until resolution to at l east baseline grade or less than 2x baseline value if baseline was Grade ≥ [ADDRESS_451314] cycle will be until the resolution is confirmed.Registration
Cycles 1-21(Core Phase) :
IV Im etelstat Day 1
Repeat every 2 8days x 2cycles
Cycles 3-92(Core Phase)
IV Im etelstat Day 1
Repeat every 2 8days 3Cycles 3 and Beyond (Core Phase)
Treat as Arm  F (Cycle 3 will start with 
Cycle 1 of Arm  Fdosing schedule)
Cycles 103and Beyond (Extension Phase)
IV Im etelstat Day 1 
Repeat every 28 days4
Event Monitoring /
Hepatic Safety Monitoring
PD at any tim e5
Unacceptable adverse events      Event
Patient refusal              
     Monitoring /
          Hepatic Safety MonitoringAny one of the following at the end of cycle 2:
Greater than 75% reduction in leukocyte count
Greater than 75% reduction in platelet count
Greater than 50% reduction in spleen size in patients with baseline palpa ble splenomegaly of >5 cm
Greater than 2 gm/dL increase in hemoglobin level from bas eline without transfusions
Yes No
Protocol CP14B019, Amendment 13
Page 13of 902In patients who do not achieve CR or PR, by [CONTACT_42334] 4, the frequency of dosing may be increased to every week or 
every 2weeks, at the physician ’s discretion. 
3For patients whose response has plateaued, without signs of further improvement, for a minimum of 3 months, dosing 
frequency may be reduced to eve ry 2 to 3 months, or treatment may be interrupted until relapse then restarted, at the 
physician ’sdiscretion.  
4Patients may continue to receive imetelstat study treatment for as long as they derive clinical benefit or until study end. T he 
study will en d when all subjects have discontinued study drug, the last patient enrolled has been treated for [ADDRESS_451315].
5Except relapse that occurs during dose interruption.  These pa tients may restart treatment at the physician ’sdiscretion per 
Section 7.1.
Protocol CP14B019, Amendment 13
Page 14of 90Figure 5: Schema –Arm F 
(Note: Arm F permanently closed to accrual) (myelofibrosis patients without spliceosome mutations or ring sideroblasts)
1Cycle length = 28 days. For all patients who did not experience a treatment emergent abnormality in liver function tests 
(LFTs), defined as any grade abnormality in patient s with normal value at baseline or any higher grade shift from baseline in 
patients with an abnormal baseline , or value more than 2x baseline if baseline was Grade ≥ 3,or hepatic adverse events are 
present at imetelstat discontinuation, obtain LFT follow -
up until [ADDRESS_451316] schedule (see 
Section 4for details) until resolution to at least baseline grade or less than 2x baseline value if baseline was Grade ≥ [ADDRESS_451317] cycle will be until the resolution is confirmed.
2In patients who do not achieve CR or PR, by [CONTACT_42334] 4, the frequency of dosing may be increased to every two w eeks,
at the physician’s discretion. Registration
Cycles 1-21(Core Phase) :
IV Im etelstat Day 1
Repeat every 2 8days x 2cycles
Cycles 3-92,3(Core Phase)
IV Im etelstat Day 1
Repeat every 2 8days Cycles 3 -9 (Core Phase)2,3,6
IV Imetelstat , Days 1, 3
Repeat every 28 days
Cycles 103and Beyond (Extension Phase)
IV Im etelstat Day 1 
Repeat every 28 days4
Event Monitoring /
Hepatic Safety Monitoring
PD at any tim e5
Unacceptable adverse events        Event
Patient refusal              
       Monitoring /
        Hepatic Safety MonitoringAny one of the following at the end of cycle 2:
Greater than 75% reduction in leukocyte count
Greater than 75% reduction in platelet count
Greater than 50% reduction in spleen size in patients with baseline palpable splenomegaly of >5 cm
Greater than 2 gm/dL increase in hemoglobin level from baseline without transfusions
Yes No
Cycles 103and Beyond (Extension Phase)
IV Im etelstat Day s 1, 3
Repeat every 28 days4
Event Monitoring /
Hepatic Safety Monitoring
Protocol CP14B019, Amendment 13
Page 15of 903For patients whose response has plateaued, without signs of further improvement, for a minimum of 3 months, dosing may be 
reduced to Day 1 every 28 days or Days 1 and 3 every 2 to 3 months or treatment may be interrupted until relapse then 
restarted, all at the physician’s discretion .
4Patients may continue to receive imetelstat study treatment for as long as they derive clinical benefit or until study end. T he 
study will end when all subjects have discontinued study drug, the last patient enrolled has been treated for [ADDRESS_451318].
5Except relapse that occurs during dose interruption.  These patients may restart treatment at the physician’s discretion per 
Section 7.1.
6If criteria still not met after Cycles 3 and 4, at the physician’s discretion , dosing might be increased to Days 1, 3, and 5 every 
28 days. 
Protocol CP14B019, Amendment 13
Page 16of 90Figure 6: Schema –Arm G 
(Note: Arm G permanently closed to accrual) (MDS/MPN or MDS patients with spliceosome mutations or ring sideroblasts)
1Cycle length = 28 days.   For all patients who did not experience a treatment eme rgent abnormality in liver function tests 
(LFTs), defined as any grade abnormality in patients with normal value at baseline or any higher grade shift from baseline in 
patients with an abnormal baseline , or value more than 2x baseline if baseline was Grade ≥ 3,or hepatic adverse events are 
present at imetelstat discontinuation, obtain LFT follow -up until [ADDRESS_451319] schedule (see 
Section 4for details) until resolution to at least bas eline grade or less than 2x baseline value if baseline was Grade ≥[ADDRESS_451320] cycle will be until the resolution is confirmed.
2In patients who do not achieve CR or PR, by [CONTACT_42334] 4, the frequency of dosing may be increased to every week or 
every 2weeks, at the physician’s discretion.
3For patients whose response has plateaued, without signs of further improvement, for a minimum of 3 months, dosing 
frequency may be reduced to every 2 to 3 months, or treatment may be interrupted until relapse, at the physician’s discretion .Registration
Cycles 1-21(Core Phase) :
IV Im etelstat Day 1
Repeat every 2 8days x 2cycles
Cycles 3-92(Core Phase)
IV Im etelstat Day 1
Repeat every 2 8days 3Cycles 3 and Beyond (Core Phase)
Treat as Arm  F (Cycle 3 will start with 
Cycle 1 of Arm  F dosing schedule)
Cycles 103and Beyond (Extension Phase)
IV Im etelstat Day 1 
Repeat every 28 days4
Event Monitoring /
Hepatic Safety Monitoring
PD at any tim e5
Unaccep table adverse events    Event
Patient refusal              
  Monitoring /
   Hepatic Safety MonitoringAny one of the following at the end of cycle 2:
Greater than 75% reduction in leukocyte count
Greater than 75% reduction in platelet count
Grea ter than 50% reduction in spleen size in patients with baseline palpable splenomegaly of >5 cm
Greater than 2 gm/dL increase in hemoglobin level from baseline without transfusions
Yes No
Protocol CP14B019, Amendment [ADDRESS_451321].
5Except relapse that occurs during dose interruption.  These patients may restart treatmen t at the physician’s discretion per 
Section 7.1.
Protocol CP14B019, Amendment 13
Page 18of 90PROTOCOL A MENDMENTS
Protocol Version Issue Date
Geron Protocol A mendment 11 
(prior to transfer to Janssen 
Research & Development )[ADDRESS_451322] recent amendment following transfer to Janssen 
Research & Development .
Amendm ent 13 (5Oct2015)
The overall reason for the am endm ent: To limit collection of follow -up st udy data to that critical for assessment 
of safety outcomes , and t o allow  subjects w ho are benefiting from imetelstat to continue to receive study treatment 
beyond 3 years.
Applicable Section(s) Description of Change(s)
Rationale: To clarify and emphasiz e that additional hepatic laboratory surveillance is explicitly required for 
subjects in safety follow -up who had ongoing treatmen t-emergent abnormalit iesinLFTs or hepatic adverse events 
when imetelstat was discontinued ,
Figures 1 -6 Revised “Event Monit oring” to “Event Monitoring/Hepatic Safety Monitoring” in the 
schematic diagrams for each treatment arm.
Rationale: To rem ove the limitation on duration of study treatment for patients who continue to derive clinical 
benefit beyond 3 years.
Figures 1 -6,footnote s
[IP_ADDRESS] Arm A 
Treatment Schedule 
(footnote 1)
[IP_ADDRESS] Arm B 
Treatment Schedule
(footnote 1),
[IP_ADDRESS] Arms C and D 
Treatment Schedule,
(footnote 1)
[IP_ADDRESS] Arms E and G 
Treatment Schedule, 
(footnote 1)
[IP_ADDRESS] Arm F Treatment 
Schedule,
(footnote 1 )
8.[ADDRESS_451323].
Rationale: The s tatus of other imetelstat studies has changed. 
1.3.[ADDRESS_451324] been added for 4 Phase II imetelstat studies. The title of 
Study CP14B015 has been corrected to add “ or Polycythemia Vera” and the study 
status has been changed from “Completed treatment (i n safety follow up) ”to 
“Completed”.
Protocol CP14B019, Amendment 13
Page 19of 90Rationale: To limit study procedures in the Extension Phase and at study completion to those needed for safety 
follow -up.
[ADDRESS_451325] Schedule , Table 3 Physical examination for hepatomegaly and splenomegaly, and transfu sion assessment 
removed as required assessments during the Extension Phase. Peripheral blood smear 
and IWG assessment of response removed as required assessments during the 
Extension Phase and at Study Completion/Early Termination. Urinalysis removed at 
Study Completion/Early termination.
[ADDRESS_451326] Schedule, 
Table 3, footnote 14Clarified to allow  a ±7-day window for hepatic event follow -up and redefine d the end 
of the Event Monitoring Phase of the study from [ADDRESS_451327] patient has completed study treatment. Follow -up 
during the Event Monitoring Phase can be completed via telephone call.
Rationale: To streamline and clarify hepatic monitoring. 
4.[ADDRESS_451328] Schedule for 
Hepatic Safety 
Monitoring ,Table 4The footnote “Concomit ant medications include alternate treatment for MPN/MDS” 
has been deleted; remaining footnotes have been renumbered accordingly.
Rationale: To clarify requirements for study drug dose modification.
8.2 Dose Reduction Sentence added to the end of the firs t paragraph clarifying that once an imetelstat dose 
reduction has occurred, the dose should not be subsequently re-escalated .
Rationale: Update description of drug preparation procedures. Reconstitution time is estimated at [ADDRESS_451329] description.
15.1.3 Preparation and 
StorageText describing lyophilized imetelstat as reconstituting easily has been deleted. 
Rationale: Minor errors w ere noted.
Throughout the 
protocolMinor grammatical, formatting, or typographical changes w ere made.
Protocol CP14B019, Amendment 13
Page 20of 90Amendm ent 1 2(21Jan 2015 )
The overall reason for the am endm ent: The overall reason for the amendment is to transfer sponsorship of this 
study from Geron to Janssen Research & Development and to update safety reportin gaccordingly .
Applicable Section(s) Description of Change(s)
Rationale: To update the language in the protocol to indicate the transfer of sponsorship from Geron to Janssen 
Research & Development and to establish the safety reporting procedures under the new sponsorship .
10.1. Safety 
Parameters and 
Definitions; 
[IP_ADDRESS]. Pregnancy ;
10.6. Post -Study 
Adverse EventsLanguage changed to indicate transfer of sponsorship.
10.4.1. Reporting 
Requirements for 
Fatal/Life Threatening 
SAEs Related to 
Investigational 
ProductDeleted the fo rmer medical monitor contact [CONTACT_362219]: 
The names (and corresponding telephone numbers) of the individuals who should be 
contact[CONTACT_362220](s), w hich will be provided as a separate document .
10.4.2. Reporting 
Requirements for All 
SAEsDeleted the former procedures for reporting SAEs and replaced w ith the new procedures.
16.7. Data and Safety 
MonitoringUpdated the member ship of the safety review committee and updated the following text
(bold text indicates additions; strikeout indicates deletions) :The Medical Monitor study 
responsible physician or Drug Safety Scientist safety physician may convene a meeting 
sooner should any concer ns arise from review of data or from the Investigator safety 
physician .
Added text to indicate that an independent hepatic safety panel will review emergent 
relevant safety data if needed.  
Rationale: To align the current protocol w ith the administrat ive amendment memorandum that was issued by 
[CONTACT_362221] [ADDRESS_451330] Schedule, 
Table 3, footnote 6Removed the check mark in the table for an abdominal ultrasound at study completion o r 
early termination (± 1 week) ;
Revised the footnote to indicate t hat a Doppler ultrasound of abdomen w ill be performed 
post baseline only as clinically indicated at the discretion of the investigator. 
4. Test Schedule, 
Table 3, footnote 9 ;
4.1. Test Schedule for 
hepatic safety 
monitoring and follow 
up after discontinu ing 
imetelstat, Table 4, 
footnote 3Revised the text to state that serum haptoglobin and reticulocyte count should be performed
only if clinically indicated.
Rationale: Included information regarding the lift of the clinical hold by [CONTACT_941] U.S. FDA .
1.3.4. 4. Hepatobiliary 
EventsAdded: F ollow ing a complete response submitted by [CONTACT_362222], the clinical hold was lifted by 
[CONTACT_941] U.S. FDA on 31 October 2014.
Rationale: To update information regarding Phase II trials with imetelstat .
Protocol CP14B019, Amendment 13
Page 21of 901.3.3. Clinical 
Experience w ith  
Imetelstat, Table 2The study status of protocol number CP14B013 w as marked as completed.
Rationale: Minor errors w ere noted.
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Protocol CP14B019, Amendment 13
Page 22of 901. BACKGROUND
1.1. Myelofibrosis
The term my elofibrosis (MF) includes both primary  myelofibrosis (PMF) and post -polycythemia 
vera/essential thrombocy themia my elofibrosis (post -PV/ET MF) (Tefferi 2011).   MF is currently  
classified as a chronic my eloproliferative neopla sm (MPN) and is characterized by  [CONTACT_362223] a nd abnormal cy tokine expression
(Tefferi 2011).   Patients with MF ty pi[INVESTIGATOR_362191], marked splenomegaly  and 
profou nd constitutional sy mptoms (night sweats, pruritus, early  satiety , bone pain, cough, fever, 
etc.). In addition, some patients might display  thrombocy topenia, leucopenia, thrombocy tosis, 
leukocy tosis, and non -hepatosplenic extramedullary  hematopoiesis ( EMH
) (Tefferi 2011).   
Current drug therapy  for MF, such as ery thropoiesis stimulating agents (ESAs), hy droxy urea and 
JAK inhibitors have not been shown to influence survival and are often us ed for palliative 
purposes onl y (Tefferi 2011).   Allogeneic stem cell transplantation (ASCT), which is so far the 
only curative option, carries a high treatment -related mortality  and morbidity (Tefferi 2011
).
The I nternatio nal Prognostic Scoring Sy stem (I PSS), used for risk stratification in PMF, uses risk 
factors assessed at time of diagnosis: age >65 y ears, constitutional sy mptoms, hemoglobin
< 10 gm/dL, leukocy te count >25 x 109/L and peripheral blood blasts >1% ( Tefferi 2011).
Subsequently , the I PSS prognostic variables were used to devise a dy namic I PSS (DI PSS) that 
can be utilized at any  point during the disease (Tefferi 2011). Most recently , DIPSS wa s further 
revised to DI PSS-plus by  [CONTACT_362224] 3 additional I PSS/DI PSS-independent risk factors, 
including red cell transfusion need, platelet count <100 × 109/L, and unfavorable kary otype
(Tefferi 2011
); the latt er includes complex kary otype or sole or 2 abnormalities that includ e +8, 
−7/7q−, i(17q), inv(3), −5/5q−, 12p−, or 11q23 rearrangement. The 8 DI PSS-plus risk factors are 
currently  used to define low (no risk factors), intermediate -1 (1 risk factor), intermediate -2 (2 or 
3 risk factors), and high ( ≥4 risk factors) risk gro ups with respective median survivals of 15.4, 
6.5, 2.9, and 1.3 y ears(Tefferi 2011 ).Patients with MF can progress into blast phase disease 
(BP-MF), defined by  [CONTACT_362225] (AM L)(i.e. 
20% or more blasts in the peripheral blood or bone marrow) .Some patients with MPN share 
certain morphologic features with those with my elody splastic sy ndromes (MDS). The WHO 
classifies such cases as MDS/MPN overlap and their clinical features a re similar to patients with 
MF (i.e. severe anemia, splenomegaly , leukocy tosis and thrombocy tosis).
1.2. Telomeres and Telomerase Inhibition
Telomeres consist of tandem repeats of the DNA sequence TTAGGG, forming a T -loop structure 
to cap the ends of all mammalian chromosomes.  Cappi[INVESTIGATOR_362192] -strand breaks (McEachern 2000 ).  
Telomeres shorten approximately  50–120 nucleotides (nt) at each cell di vision (Harley 2002 ;
Harley  1997).   When telomeres get critically  short, they  can no longer cap the telomere ends, thus 
destabilizing the T -loop and exposing a 3’ overhang which triggers a DNA damage signal, 
ultimately  resulting in senescence, terminal differentiation, or apoptosis.  Telomere loss is 
prevented by  [CONTACT_362226], which consists of two essential 
Protocol CP14B019, Amendment 13
Page 23of 90components:  the human telomerase RNA template (hTR) and t he human telomerase reverse 
transcriptase (hTERT) cataly tic subunit.  Telomerase counters telomere loss by  [CONTACT_362227] (Harley  1997).
Normal somatic cells have relatively  long telo meres (~9 –12 kilobases) (Rufer 1999) and ty pi[INVESTIGATOR_362193]. In contrast, telomerase activity  has been detected 
in 80 –90% of cancers tested to date ,and is key  to cell immortalization through maintenance of 
telomere length (TL) (Shay
1997).   Most tumors have shorter telomeres, compared to their 
normal tissue counterparts, in spi[INVESTIGATOR_362194].  These two characteristics make 
telomerase a p romising therapeutic target for cancer.
1.3. Imetelstat
Imetelstat (GRN163L ) is a covalently -
lipi[INVESTIGATOR_300389] 13- mer thiophosphoramidate oligonucleotide that 
acts as a potent specific inhibitor of telomerase.  Telomerase inhibition leads to the loss of a 
cancer cell’s ability  to maintain TL , resulting in cell -cycle arrest, apoptosis, or senescence.  The 
mechanism of action of imetelstat is not an antisense -based approach.  I metelstat does not cause 
down regulation of mRNA encoding either the hTR or hTERT subunits of te lomerase, nor does it 
affect RNAse H activity , which ty
pi[INVESTIGATOR_362195].  I metelstat binds with high affinity  to hTR and is a 
competitive inhibitor of telomerase enzy matic activity (Asai 2003; Herbert 2005 ).  Studies have 
shown that treatment of various cancer cells with imetelstat in vitro increases their sensitivity  to 
radiation, decreases their clonogeni c potential, and results in altered expression of stem -cell 
related genes (Stewart 2010) ( Harley  2008 ).
1.3.1. Nonclinical Pharmacology
[IP_ADDRESS]. Efficacy Studies
Data from nonclinical efficacy  studies hav e shown that imetelstat inhibits telomerase in tumor 
cells and compromises cancer cell viability  in vitro.  I metelstat has broad tumor growth inhibition 
activity  in multiple xenograft models, including non -small cell lung, breast, colorectal, 
pancreatic, g lioblastoma multiforme (GBM), my eloma, neuroblastoma, hepatic and ovarian 
cancers.
[IP_ADDRESS]. Effects on Cancer Stem Cells
Numerous studies have identified a relatively  rare subpopulation of tumor -initiating cells (TI Cs), 
also termed cancer stem cells (CSCs), in mult iple cancer ty pes.  CSCs are distinct from the bulk 
tumor cell population, y et share the properties of increased telomerase activity  (TA) and short 
telomeres, making CSCs of multiple tumor ty pes promising targets for telomerase inhibition.  I n 
vitro studie s have demonstrated that imetelstat inhibits telomerase ,and is effective in targeting 
CSCs from my eloma, melanoma, breast, pancreatic, pediatric glioma, neuroblastoma, prostatic, 
lung and glioblastoma multiforme tumor ty pes ( Joseph et al. 2010b ; Marian et al. 2010 a).  
Treatment of CSCs with imetelstat results in increased apoptosis, induction of senescence, and 
inhibition of proliferation, sphere formation, and clonogenicity .  In vivo stud ies demonstrated 
that imetelstat is able to significantly  inhibit CSC -mediated tumor engraftment and growth in 
Protocol CP14B019, Amendment [ADDRESS_451331], pancreatic, glioblastoma, neuroblastoma, and my eloma xenograft models ( Joseph et al. 
2010a ; Hochreiter 2006; Shammas 2008; Dikmen 2009 ;Castelo- Branco 2011 ;Marian 2010 b).
1.3.2. Nonclinical Safety Studies
Imetelstat was evaluated in a broad range of toxicology  studies to support its use as a 
systemically- delivered anticancer agent in humans.  The general toxicology  of imetelstat was 
assessed in rodents and non -human primates.  Imetelstat nonclinical safety  studies were carried 
out in mice, rats, rabbits, and cy nomolgus monkeys.  Support for the proposed clinical dose and 
schedule is based primarily  on the repeat -dose studies in mice (dosed twice weekly  for 26 weeks) 
and cy nomolgus monkey s (dosed once weekly  for 9 months).
Toxicities generally  fit into two main categories:  (1) those related to plasma concentrations of 
imetelstat, reflecting interactions with blood components, and (2) those reflecting tissue 
deposition and associated inflammatory  effec ts, as were evident from histopathology  evaluations.
Toxicities observed with imetelstat treatment included cy topenias, complement activation, and 
coagulation abnormalities.  Complement activation and coagulation abnormalities were related to 
plasma concentrations of imetelstat.  The etiology  of the cy topenias is not clear; a direct effect on 
hematopoietic progenitor cells cannot be excluded.
Early  intravenous (I V) bolus range -finding studies helped define the high -dose toxicity  profile 
and repeat -dose studies characterized the full range of potential target organs for imetelstat -
related adverse effects.  At high doses in rodents (i.e., ≥30 mg/kg I V bolus), effects on 
hematology  and coagulation parameters were observed, including elevated activated partial 
thromboplastin time (aPTT), hemorrhage, and decreased platelet and red blood cell pools.  The 
occurrence of peripheral cy topenias, most notably  thrombocy
topenia, was sometimes 
accompanied by  [CONTACT_362228] (RBC) parameters and mild anemia.  I n non- human 
primates, hematological effects (decreases in RBC parameters and platelets at doses ≥15 mg/kg) 
were present but to a lesser extent than those seen in rodents.  I n ex vivo colony -forming assay s 
using human bone marrow progenitors, imetelstat did n ot significantly  inhibit ery throid or 
myeloid colony  number (although colony  morphology  was compromised at 15 M), but 
megakary ocyte colony  growth was inhibited at ≥3.75 
μM (50% inhibitory  concentration [I C50] ~5 
μM).
Inhibition of coagulation (aPTT prolon gation) and activation of complement pathway s (increased 
plasma levels of Bb and C5a split products and decreased total hemoly tic complement [CH 50]) 
were noted.  These effects were reversible and similar to acute blood level -related toxicities seen 
with ot her poly anionic oligonucleotides.  There was no clinical evidence of clotting 
abnormalities in monkey s at relatively  high doses that produced over 3 -fold increases in aPTT.
Severe complement -mediated adverse reactions were noted in some of the monkey  dose -finding 
studies; however chronic complement activation at doses ≤ 15 mg/kg did not result in any  
adverse constitutional outcomes.  Similar to other oligonucleotides in this class, imetelstat -
mediated activation of the alternative complement pathway  is beli eved to stem from binding to 
an inhibitory  complement protein (Factor H), which, if sufficiently  depleted, initiates an 
activation cascade with the formation of biologically  active split products culminating in 
Protocol CP14B019, Amendment 13
Page 25of 90hemody namic changes (mainly  hypotension).  I nmonkey s, this may  result in significant 
cardiovascular toxicity .  In the case of imetelstat, the threshold blood level for complement 
activation is approximately  200  g/mL.  Toxicokinetic analy ses confirmed that these acute 
effects are reversible after 24 hours and can be managed by  [CONTACT_362229].
Administration of imetelstat intravenously
 to monkey s at doses of up to 15 mg/kg over 2 hours 
once weekly  for 9 months was well tolerated.  Data from studies in rats su ggested that imetelstat 
was taken up by  [CONTACT_362230], primarily  liver, kidney s and, to a lesser extent, the spleen and bone 
marrow; these are the target organs for histopathologic alterations.  Microscopic examination of 
tissues revealed mild to moderate c hanges in the kidney  (mesangial thickening, 
glomerulonephritis/sclerosis, deposition in interstitium, renal tubular hemorrhage, protein casts, 
and regeneration), liver (telangiectasis and deposition in Kupffer cells), uterus (atrophy  of the 
endometrium), c horoid plexus (minimal ly mphoid follicle formation and mononuclear cellular 
infiltration), and general sy stemic arteritis including at the injection site at doses starting at 
5mg/kg.  The observations in the kidney  did not show signs of reversibility  in the recovery  group 
animals; however, it is not unusual for such inflammatory  lesions to persist for several months in 
monkey s.  The endometrial atrophy  was only  noted after 9 months of chronic dosing at 15 mg/kg 
and was absent in the recovery  animals.  The remaining morphological changes in the liver and 
the inflammatory  vasculitis (choroids plexus and sy stemic arteritis) showed signs of resolution in 
the recovery  group animals.
Most of these histological findings are thought to be due to pro -inflammatory  activity  common to 
many  oligonucleotides and derived from a programmed phy siological reaction of the body  to 
their foreign nucleic acid structure and are heightened when the molecule is chemically  modified 
to inhibit degradation by  [CONTACT_362231].  I n general, the changes observed in the groups 
that received imetelstat at doses up to 15 mg/kg were of limited severity  and were not associated 
with any  tissue degeneration or other alterations that would suggest compromised organ function. 
Most changes sho
wed evidence of recovery  after a 14 -week drug -free period.
Imetelstat was not teratogenic in mice or rabbits following bolus or 2 -hour continuous 
intravenous (I V) infusion of 30 mg/kg.  I n rabbits, embry o-lethality  was noted as increased post -
implantation loss at 30 mg/kg due to an increase in early  resorptions, resulting in higher 
incidence of litter loss at this dose level that correlated to a decrease in litter size and viable 
fetuses.
Additional findings from nonclinical studies that may  predict the saf ety of the clinical dose 
include:  (1) absence of effects on cardiovascular (human ether -à-go-go related gene [hERG] 
inhibition, electrocardiogram [ECG]), respi[INVESTIGATOR_696] , and neurological function, and (2) absence of 
genetic toxicity  in tests for mutagenicity and clastogenicity .
Please refer to the I metelstat I nvestigator’s Brochure (IB) for further details.
1.3.3. Clinical Experience with Imetelstat
Table 1and Table 2summarize all clinical trials with imetelstat initiated by  [CONTACT_362232].
Protocol CP14B019, Amendment [ADDRESS_451332] been initiated since 2005, of which three were single -agent studies and 
three were combination studies.  The study  designs and status are summarized below and 
presented in Table 1.  A total of 183 patients we re treated with imetelstat in Phase I ; enrollment 
and study  treatment has been completed and the databases locked for all six studies.  
In Phase I I clinical trials, imetelstat was investigated as a single agent in CP14B015 (ET/PV), as 
single -agent or comb ination therapy  in CP14B013 (multiple my eloma [± lenalidomide]) and 
CP14B012 (NSCL C [± bevacizumab]), and as combination therapy  in CP14B014 (MBC 
[paclitaxel ± bevacizumab]).  As of 21 May  2013, a total of 191 patients were treat ed with 
imetelstat in Phase II (Table 2).
Protocol CP14B019, Amendment 13
Page 27of 90Table 1: Phase I Clinical Trials with Imetelstat
Protocol 
Num berProtocol TitlePatients 
EnrolledPatients 
Treated 
(Data Cut -
off Date)Dose and Schedule of Im etelstat Key Study EndpointsStudy 
Status
Single Agent Trials
CP14A004 A Phase I Sequential Cohort, Dose Escalation Trial to 
Determine the Safety, Tolerability, and Maximum 
Tolerated Dose of Weekly Administration of 
GRN163L in Patients with Refractory or Relapsed 
Multiple Myeloma20 20
(Locked 
15Nov2010)3.2, 4.8, 6.0, 7.2 mg/kg over 2 
hours weekly; 6.0 mg/kg on Days 
1, 8 every 21 days.Primary :  Safety, tolerability, 
MTD
Secondary : PK, anti -tumor 
activity, pharmacodynamicsCompleted
CP04 -151 A Phase I/II , Sequential Cohort, Dose Escalation Trial 
to Determine the Safety, Tolerability, and Maximum 
Tolerated Dose of Weekly Administration of 
GRN163L in Patients with Refractory or Relapsed 
Chronic Lymphoproliferative Disease28 28
(Locked 
15Feb2011)20, 40, 80 , 160, and 240 mg/m2
over 6 hours w eekly; 160 and 
200mg/m2over 2 hours w eekly; 
200 mg/m2over 2 hours on Days 1 
and 8Primary :  Safety, tolerability, 
MTD
Secondary : PK, anti -tumor 
activity, pharmacodynamicsCompleted
CP05 -101 A Phase I, Sequential Cohor t, Dose Escalation Trial 
to Determine the Safety, Tolerability, Maximum 
Tolerated Dose, and Optimal Infusion Duration of 
Weekly Administration of GRN163L in Patients with 
Refractory or Relapsed Solid Tumor Malignancies75 75
(Locked 
21Mar2011)0.4, 0.8, 1. 6, 3.2, 4.8 mg/kg over 2 
hours weekly; 4.8, 6.0, 7.5, 9.4, 
11.7 mg/kg on Days 1, 8 every 21 
days; 9.4, 11.7 mg/kg once every 
28 daysPrimary :  Safety, tolerability, 
MTD
Secondary : PK, anti -tumor 
activity, pharmacodynamicsCompleted
Com bination Trials
CP14A005 A Phase I Sequential Cohort, Dose Escalation Trial to 
Determine the Safety, Tolerability, and Maximum 
Tolerated Dose of Weekly Administration of 
GRN163L in Combination with Paclitaxel and 
Carboplatin in Patients w ith Advanced or Metastatic 
Non-Small Cell Lung Cancer27 27
(Locked 
15Oct2010)3.2 mg/kg over 2 hours weekly; 
3.2mg/kg over 2 hours once every 
21 days; 3.2, 4.8, 6.0 and 7.5 mg/kg 
on Days 1, 8 every 21 days.Primary :  Safety, tolerability, 
MTD
Secondary : PK, anti -tumor 
activity Completed
CP14A011 A Phase I Study of GRN163L in Combination with 
Bortezomib and Dexamethasone in Patients with 
Relapsed or Refractory Multiple Myeloma9 9
(Locked 
15Dec2010)160, 200 mg/m2over 2 hours Days 
1, 8 every 21 daysPrimary :  Safety, tolerability
Secondary : PK, anti -tumor 
activity Completed
CP14A010 A Phase I/II Study of GRN163L in Combination with 
Paclitaxel and Bevacizumab in Patients with Locally 
Recurrent or Metastatic Breast Cancer24 24
(Locked 
28Mar12)160, 240, 300, 375 mg/m2Days 1, 
8, 15 every 2 8 days; 300 and 375 
mg/m2Days 1, 15 every 28 days; 
300 mg/m2 Day 8 every 28 days.Primary :  Safety, tolerability
Secondary : PK, anti -tumor 
activity Completed
Protocol CP14B019, Amendment 13
Page 28of 90Table 2: Phase II Trials with Imetelstat
Protocol 
Num berProtocol TitlePatients 
EnrolledPatients 
Treated Dose and Schedule of 
ImetelstatKey Study Endpoints Study 
Status
Randomized Trials
CP14B012A Randomized Phase II Study of Imetelstat as 
Maintenance Therapy after Initial Induction 
Chemotherapy for Adv anced Non -Small Cell 
Lung Cancer (NSCLC)116114
(Locked 
19Sep20139.4 mg/kg over 2 hours 
on Days 1,8 every 21 
daysPrimary :  PFS
Secondary : Safety, tolerability, 
ORR Completed
CP14B014A Randomized Phase II Study of Imetelstat 
(GRN163L) in Combination w ith Paclitaxel 
(With or W ithout Bevacizumab) in Patients with 
Locally Advanced or Metastatic Breast Cancer166161
(Locked 
10Dec2012)300 mg/m2on Day 1 
every 21 daysPrimary :  PFS
Secondary : Safety, ORR, clinical 
benefit rateCompleted 
(early 
termination)
Single -Arm Trials
CP14B013A Phase II Trial to Determine the Effect of 
Imetelstat (GRN163L) on Patients with 
Previously Treated Multiple Myeloma1313
(Locked 
20Nov2014)9.4 mg/kg over 2 hours 
on Days 1,8 every 28 
daysPrimary:  Improvement in response
Secondary: Safety, tolerability, 
PFS, circulating mye loma CSCsCompleted 
CP14B015A Phase II Trial to Evaluate the Activity of 
Imetelstat (GRN163L) in Patients with Essential 
Thrombocythemia or Polycythemia Vera who 
Require Cytoreduction and Have Failed or Are 
Intolerant to Previous Therapy, or w ho Refuse 
Standard Therapy2020
(Locked 
06Apr2015)7.5 -11.7 mg/kg over 2 
hours weekly or as 
needed based on 
hematologic responsePrimary:  Hematologic response 
(ET), Hematocrit (PV)
Secondary : Safety, tolerabili ty, 
duration of hematologic, response, 
molecular resp onse, histologic 
response at 2 years, on study, 
phlebotomy rate (PV)Completed  
Protocol CP14B019, Amendment 13
Page 29of 901.3.4. Safety Experience
The overall summary  of clinical safety  for imetelstat is primarily  based on the 374 imetelstat 
treate d patients in all 10 Geron sponsored Phase I  and I I trials to date. Where relevant, additional 
clinical safety  information (
e.g.,from investigator -sponsored trials )is incorporated. For 
additional details, refer to the I B.  A summary  of clinical safety  is provided below.
[IP_ADDRESS]. Hematologic Events
Cytopenias, in particular thrombocy topenia, were dose -limiting in both single -agent imetelstat 
trials and when combined with other chemotherapi[INVESTIGATOR_014].  The frequency  and severity  of all 
cytopenias, particularly  thrombocy topenia and neutropenia, were associated with the dose 
intensity  (dose and frequency  of dosing) of imetelstat, concomitant administration with other 
cytotoxic agents, the number and nature of prior chemotherapy
 regimens to which patients had 
been exposed, an d low marrow reserve. 
Grade [ADDRESS_451333] epi[INVESTIGATOR_119988] 3 -4 
thrombocy topenia was observed as late as Cy cle 7 with single -agent imetelstat.  Recovery  to 
Grade ≤ 1 usually  occurred within 1 [ADDRESS_451334] 
observed epi[INVESTIGATOR_362196] 29 in single -agent trials.  R esolution to Grade ≤ 1 
typi[INVESTIGATOR_362197] 1 [ADDRESS_451335] inhibition 
of telomerase in hematopoietic progenitor cells or the non -specific toxicity  related to the 
molecular class of the compound.  
During the course of the current my elofibrosis trial CP14B019 (formerly  MC1285) more 
persistent and profound my elosuppression, particularly  thrombocy topenia, was observed. In the 
cohort (B) treated with an initial intensive we
ekly regimen for four doses, two patients developed 
profound prolonged cy topenias following the last dose in the weekly  dosing period.  One patient 
recovered after holding the dose and was retreated at a lower dose and schedule 16weeks after 
her last imet elstat dose.  The second patient experienced associated clinical outcomes of febrile 
neutropenia and a fatal intracranial hemorrhage (I CH) in the setting of Grade [ADDRESS_451336] been associated with thrombocy topenia in Geron sponsored trials; these 
may be serious and severe enough to be potentially life threatening.  The most frequently  
observed event wa s epi[INVESTIGATOR_3940]. There have been two fatal bleeding events of I ntracranial 
hemorrhage ( ICH) in the setting of Grade [ADDRESS_451337] 
enrolled in CP14B019 (formerly  MC1285) , as noted above, who experienced a fatal I CH 
following profound Grade [ADDRESS_451338] cy cle of imetelstat.
Febrile neutropenia has been observed at a low incidence, particularly  in combination with 
taxanes.  Since Grade 3 and 4 neutropenia with imetelstat treatment is observed quite frequently , 
patients shoul d be closely  monitored for infections and appropriate management instituted per 
institutional standards to mitigate and manage potentially  life threatening infections.  
[IP_ADDRESS]. Coagulation Changes
In the Phase I imetelstat trials in which serial aPTT was measured following infusion, transient 
aPTT prolongations were observed in all patients which, at doses ≥ 3.2 mg/kg and 160 mg/m2, 
were as high as Grade 3.  Resolution to Grade [ADDRESS_451339] that aPTT prolonga tion is correlated with plasma concentrations of 
imetelstat.  PT prolongations occurred infrequently  and the majority  was Grade 1.  I n the Phase I I 
trials, aPTT and PT were not routinely  measured.  No bleeding events associated with 
coagulation abnormalities were reported in these trials.
[IP_ADDRESS]. Infections
Infections are frequently  reported across all imetelstat trials, with an overall incidence of 43.0%.  
The most frequently  reported events are urinary  tract infection and upper respi[INVESTIGATOR_37193]. 
Most patients had normal neutrophil counts proximal to the infection epi[INVESTIGATOR_1841]. 
Febrile neutropenia is infrequent and significant infections attributed to imetelstat associated 
with Grade ≥ [ADDRESS_451340] not been reported.  
[IP_ADDRESS]. Hepatobiliary Events
Abnormali ties in serum aminotransferases (i.e., alanine aminotransferase [AL T] and aspartate 
aminotransferase [AST]) or alkaline phosphatase (ALP) with, in some cases, accompany ing 
bilirubin elevations were observed in patients in the Phase I I ET/PV trial (CP14B015 ).  
Elevations in AL T and AST appear to be early , self -limiting and Grade [ADDRESS_451341] also been observed (4 patients/20%) at the 9.4 mg/kg 
weekly  dose level, and these resolved to baseline with imetelstat dose holds and dose reductions. 
Persistent Grade [ADDRESS_451342] also been 
reported.  Bilirubin fractionations were primarily  unconjugated among these patients. The 
clinical significance of these persistent AL P elevations and reversibility  upon stoppage of 
imetelstat is not understood at present and remains under close monitoring.    
Protocol CP14B019, Amendment 13
Page 31of 90In this trial (CP14B015) an  y ear old  patient, who had been receiving imetelstat for 
almost [ADDRESS_451343] having multiple comorbidities and concomitant 
medications making assessment of the role of imetelstat extremely  challenging, though it cannot 
be definitely  excluded.
The low grade liver biochemistry  patterns observed in CP14B015 trial were also observed in 
other imetelstat trials, but with lesser frequency , which may  be somewhat attributable to shorter 
treatment and observation time on study  in advanced malignancy  trials.  The abnormal laboratory  
observations may  be dose related and may  be more frequent when imetelstat is administered in 
combination with other cy totoxic ag ents.  The majority  of findings attributable to imetelstat are 
biochemical abnormalities without clinical sequelae and do not appear to be clinically  significant 
in patients with advanced malignancies.  Severe hepatobiliary events, including fatal outcomes
may, however, occur in these patients.  Refer to I B Section [IP_ADDRESS] for further details. 
On 11 March 2014, the [LOCATION_002] Food and Drug Administration (U .S.FDA) issued Geron a 
full clinical hold citing lack of evidence of reversibility  of hepatotoxic ity, risk for chronic liver 
injury ,and lack of adequate follow up in subjects who experienced hepatotoxicity . 
All subjects 
enrolled in Geron- sponsored clinical trials permanently  discontinued imetelstat treatment and 
enrollment of new subjects to clinica l trials was not allowed. Continued safety  surveillance was 
implemented as part of an extended hepatic safety  follow -up period of all subjects in ongoing 
Geron -sponsored trials who had liver biochemistry  abnormalities and/or hepatic adverse events 
that fi rst appeared during imetelstat treatment, or worsened from baseline during treatment, and 
were continuing at the time subjects’ discontinued imetelstat treatment. Reversibility  of these 
abnormalities and/or hepatic adverse events back to normal or baselin e levels after discontinuing 
imetelstat were assessed. Data were collected from subjects who discontinued imetelstat 
treatment as a result of the clinical hold, as well as those who discontinued for any  reason and 
met safety  follow -up criteria prior to th e clinical hold. Following a complete response submitted 
by [CONTACT_362222], the clinical hold was lifted by  [CONTACT_941] U.S. FDA on [ADDRESS_451344] party  
hepatology  experts will be consulted as necessary to continue to refine the understanding of this 
signal as data emerge.

Protocol CP14B019, Amendment 13
Page 32of [IP_ADDRESS]. Infusion Reactions
Oligon ucleotides have been previously  reported to cause complement activation and related 
infusion reactions with the potential to cause non -complement -related hy persensitivity  reactions. 
In the Phase I I trials where all patients had routine prophy laxis, 19.4% of imetelstat -treated 
patients had an infusion reaction.  The events are sporadic and a patient may  not necessarily  
experience a subsequent event with successive infusions. Infusion reactions are generally  mild to 
moderate in severity  but symptoms and sig ns may  occasionally  be Grade 3 or 4 (incidence 3%) in 
severity .  Reactions may  be more frequent or severe with imetelstat dose levels exceeding 9.4 
mg/kg.  Reactions may  be ameliorated, but are not alway s prevented, by  [CONTACT_362233], diphenhy dramine, and/or acetaminophen.
[IP_ADDRESS]. Gastrointestinal Events
Gastrointestinal events of all grades are some of the most frequently  reported events reported 
with imetelstat -treatment.
Nausea is the most frequent event. Diarrhea, vomiting, abdomin al pain, and constipation were 
also frequently reported.  These events resolve between infusions, usually  within [ADDRESS_451345] been observed in 2 
patients receiving imetelstat in combination with taxane chemotherapy , which may  be the main 
contributor to the event. The majority  of the epi[INVESTIGATOR_362198], including all Grade 3 
events.
[IP_ADDRESS]. Constitutional Symptoms
Constitutional sy mptoms within a few day s of imetelstat infusion, including headache, nausea, 
vomiting, diarrhea, fatigue, my algia, arthralgias, fever, flu- like illness, and chills are frequently  
observed with imetelstat treatment, consistent with what has been reported with other 
oligonucleotides.  These s ymptoms are also common in oncology  patients.  The events are 
usually  self-limiting, are mostly  Grade [ADDRESS_451346] frequently  reported Grade 3 event was fatigue. Other Grade 3 events were diarrhea, 
musculoskeletal pain, and nausea, all observed in less than 2% of these patients.  No Grade [ADDRESS_451347] -PV/ET MF, BP -MF and MDS/MPN are diseases associated with high morbidity  and 
mortality  and in whom currently available medications, including the recently  developed JAK 
inhibitors, carry  minimal impact on the natural history  of the disease including overall and 
leukemia -free survival. The currently  available drugs have so far failed to favorably  affect bone 
marrow pathology
, cytogenetic abnormalities, JAK2V617F allele burden and have had limited 
effect in alleviating anemia or controlling leukocy tosis or thrombocy tosis. JAK inhibitors have 
been shown to provide benefit in reducing spleen size and alleviating sy mptoms but do not 
appear to offer any  additional value.   Furthermore, these medications are often associated with 
side effects, including anemia and thrombocy topenia.
The key  obstacle to the value of JAK inhibitor therapy  in MF is the fact t hat the disease is not 
necessarily  defined by  a JAK -STAT -relevant mutation and that its molecular pathogenesis 
includes many  other mutations and aberrant pathway s.Imetelstat may  be particularly  beneficial 
in this regard since it targets abnormal prolifer ation regardless of its molecular underpi[INVESTIGATOR_11423]. In 
addition, the drug has the following properties that are relevant to patients with MF and 
MDS/MPN:
Ability  to target CSCs and TI Cs
Inhibition of colony -forming unit -megakary ocytes (CFU -Mk) in vitro. 
Ability to target diseases with short TL , such as my eloproliferative neoplasms
Ability  to inhibit telomerase, which is highly  active in leukocy tes of patients with 
myeloproliferative neoplasms.
Longer imetelstat PK residence time in the bone marrow and spleen
, compared to 
plasma
While TA is generally  undetectable in normal somatic cells, it is expressed in approximately  85% 
of human cancers as well as in cancer progenitor cells, which are believed to play  a critical role 
in dy sregulated cell growth and tumor m etastasis ( Harley  2008).  TA (as measured in 
granulocy tes) is notably
 high in patients with my eloproliferative neoplasms (Ferraris 2005a ).  
Additionally , TL (measured in granulocy tes) in pa tients with my eloproliferative neoplasms is 
short, regardless of JAK2 mutational status; therefore, telomerase inhibition could potentially  
benefit both JAK2 V617F and JAK2 wild
-type patients (Terasaki 2002; Ferraris 2005 b;
Bernard 2009).
Imetelstat is a potent, specific inhibitor of telomerase.  I n ex-vivo studies of normal progenitor 
cells, imetelstat did not inhibit ery throid or my eloid colony  number or 
proliferation (CFU -E, 
BFU -E, total ery throid, CFU -GM, CFU -GEMM, or total colony  forming cells).  I metelstat did 
selectively  reduce megakary ocyte colonies in culture, but only  CFU -Mk large colonies, which 
represent megakary ocyte colonies derived from the mo st primitive lineage -restricted progenitor 
cells (data on file; see Figure 4).  This suggests a sensitivity  of early  megakary ocyte progenitors
to imetelstat compared to more mature megakary ocytes.  This sensitivity  appears to coincide with 
Protocol CP14B019, Amendment [ADDRESS_451348] high 
TA and short TL .  Due to the low or transient expression of telomerase in normal tissues, 
including normal stem cells, and generally  longer telomeres in normal cells vs. tumor cells, a 
degree of tumor specificity  may  be provided with imetelstat.
1.4.1. Rationale for Dose and Schedule
Nonclinical studies indicate that imetelstat inhibits TA for 3 –[ADDRESS_451349] various starting dos
eschedules that include 
weekly  dosing to every  three weeks dosing is to find the balance between efficacy  (need drug 
present to inhibit telomerase) and toxicity. 
Protocol CP14B019, Amendment 13
Page 37of 90and 11.7 mg/kg Day 1 every  28 day s.  Doses of 7.5 mg/kg and above led to exposure in patients 
that was above that associated with tumor growth inhibition in xenograft models (see Figure 9).
Figure 9: Imetelstat Weekly AUC infin Patients and in Xenograft Mice
In the Phase I  study  in patients with solid tumors, imetelstat 4.8 mg/kg weekly  was the highest 
weekly  dose studied.  At this dose, in this heavily  pretreated population, there was no dramatic 
reduction in platelet counts in patients whose baseline platelet counts were > 250 x 103/μL.  In 
the higher dose cohorts (7.5, 9.4, and 11.7 mg/ kg) in which imetelstat was given on Day s 1 and 8 
of 21 -day cy cles, there was a greater reduction in platelet count compared to the 4.8 mg/kg 
weekly  cohort.  The greatest impact on platelets was observed in the 9.4 mg/kg and 11.7 mg/kg 
cohorts.  A reductio n in platelet counts of approximately  30% from baseline usually  occurred 
after three to six doses in the lower dose cohorts (weekly  schedule) and after two to three doses 
in the higher dose cohorts (Day s 1 and 8 every  21 day s schedule).  Hematologic toxici ty was 
generally  mild to moderate in the 7.5 mg/kg dose cohort and occurred less frequently  compared 
with the 9.4 and 11.7 mg/kg dose cohorts of heavily  pretreated patients with solid tumors.  Grade 
4 thrombocy topenia was reported in one patient in each of the 9.4 mg/kg and 11.7 mg/kg dose 
cohorts and Grade 4 neutropenia was reported in 2 patients in the 9.4 mg/kg dose cohort.  
However, dosing on Day s 1 and 8 were not held until these cy topenias occurred in Cy cle 2.  
Protocol CP14B019, Amendment 13
Page 38of 90There were no cases of Grade 3 or Grade 4 thrombocy topenia in the 9.4 mg/kg and 11.7 mg/kg 
every  28 day s cohorts and one case of Grade 3 neutropenia in the 11.7 mg/kg dose cohort.  
In patients with ET, weekly  dosing (7.5 to 11.7 mg/kg) was well tolerated with few Grade 3 or 
Grade 4 hematologic or non- hematologic toxicity  (Baerlocher et al . 2012) ; Grade 3 or 4 adverse 
events regardless of attribution included: Grade 4 non-febrile neutropenia 14.3%, Grade 3
neutropenia 28.6%, no Grade 3 or Grade 4 thrombocy topenia
,Grade 3 anemia (probably  
unrelated) 7.1%, Grade 3 increase in transaminases 14. 3%, Grade 3 infusion reactions 7.1%, 
Grade 3 infection ( cellulitis) 7.1%, Grade 3 fatigue, Grade 3 bleeding events (post -operative) 
7.1% and Grade 3 headaches 7.1% . Based on th ese data, we want to start with an every  21-day
schedule
, to first evaluate safety  in our MF patient population and subsequently  proceed with 
weekly  dosing to maximize efficacy .The particular strategy  was chosen because of the fact that 
patients with MF might be even more vulnerable for the my elosuppressive side effects of the 
drug.Accordingly , we plan to start with the first cohort of 11 patients receiving 9.4 mg/kg/ every  
21 day s,complemented with appropriate dose reduction in case of toxicity  to 7.5 mg/kg and 6 
mg/kg every  [ADDRESS_451350] 3 
cycles, it has become apparent that the every  21 day s schedule was safe and no Grade 3 or Grade 
4 non- hematologic tox icities were observed . The experience was the same for the second 11 -
patient cohort in Arm B where patients received weekly  treatment x 4 followed by  [INVESTIGATOR_135]  3weeks 
treatment.
Based on this experience in 22 patients, an Arm C cohort was recently  added where 
patients were to receive weekly  treatment until toxicity  ensued. However, it recently  came to our 
attention that a subset of patients experienced severe Grade 4 myelosuppression and th esevery 
same patients were also the ones who ultimately  responded t o treatment. Close scrutiny  allowed 
us to discover that some of the imetelstat -sensi tive patients display ed bone marrow ring 
sideroblasts, which is a morphological feature that is known to be highly  associated with 
spliceosome mutations. We followed up w ith this discovery  and under a separate I RB-approved 
laboratory  protocol, we discovered that virtually  all of our patients that suffered Grade 4
myelosuppression (and treatment response) were spliceosome -mutated. As such we are making 
the current protocol amendment that includes the following:
Abandon Arm C and assign the 11 patients slotted to be enrolled in Arm C to either 
Arm A (if spliceosome -mutated) or Arm B (spliceosome unmutated)
Consolidate Arms A, B and C (total n = 33) for the purposes of commun ication of 
results at meeting and publication of results.
Add three additional arms (Arms E, F and G) that build on our aforementioned novel 
observations and allow a more accurate and safer treatment strategy  that takes into 
account spliceosome mutational status.
These amendments are done to hopefully maximize response rate without undermining safety  
profile (Baerlocher et al. 2012). To that effect, we plan to include patients with BP -MFand 
spliceosome
-mutated MDS/MPN or M DS, considering their poor prognosis and absence of 
effective therapy  for such patients.
Protocol CP14B019, Amendment 13
Page 39of 902. GOALS 
2.1. Primary
To evaluate overall response rate in each arm. For the purposes of this protocol, 
response for Arms A, B, C, E, and F will be according to I WG-MRT crit eria (see 
Section 11). For arm G response will be according to the International Working 
Group response assessment as reported by  [CONTACT_248286] . ( 2006; Section 11.2). 
Response for Arm D is defined by  [CONTACT_362234] <5% and lasting for at least 2 months (see Section 16.2).
2.2. Secondary
To evaluate the s
afety  and tolerability  of imetelstat in each arm (per NCI CTCAE, 
v4.0).
To evaluate the efficacy  of imetelstat in the reduction of spleen size, as measured by  
[CONTACT_5292] (palpable distance from the left costal margin) in each arm.
To evaluate th e efficacy  of imetelstat in improving anemia or inducing red blood cell 
transfusion- independence in previously  transfusion- dependent patients (per I WG-
MRT criteria; see S ection 11) in each arm.
To evaluate onset 
and durability  of response as defined in primary  and secondary  
endpoints in each arm .
2.3. Exploratory
To evaluate the effect of imetelstat on bone marrow histology , kary otype, and 
JAK2V617F allele burden in each arm.
To evaluate the effect of imetelstat on leukocy tosis, circulating blast count
(blast % xWBC) , circulating immature my eloid cell count (sum of blast, 
promy elocy te, my elocy te and metamy elocy te % x WBC) ,and thrombocy tosis in each 
arm.
Protocol CP14B019, Amendment 13
Page 40of 903. PATIENT ELIGIBILITY
3.1. Inclusion Criteria
Diagnosis of one of the following
Arms A, B, E, and F only : PMF per the revised World Health Organization 
(WHO) criteria ( Appendi x B), 
Arms A, B, E, and F only : post-ET/PV MF per the I WG-MRT criteria 
(Appendix C ).
Arm D o nly: Blast -phase MF defined as the presence of 20% or more blasts in the 
peripheral blood or bone marrow 
Arm G only :  MDS/MPN or MDS patients with spliceosome mutations including 
SF3B1, SRSF2 and U2AF1 mutations or ring sideroblasts . Diagnosis of 
MDS/MPN and MDS is per WHO criteria ( Tefferi and Vardiman 2008).   Direct 
sequencing will be used to confirm the presence or absence of spliceosome 
mutations
.
Indication for treatment of one of the following: 
Arms A, B, E and F only: High -risk or I ntermediate -2 risk MF (as defined by  [CONTACT_362235] I nternational Prognostic Scoring Sy stem [DI PSS-plus]; Appendix A )
.
Arm G only : presence of severe anemia defined as hemoglobin of <9 g/dL or 
other indication s for cy toreductive therapy per phy sician discretion
Presence of the following: 
Arms E and G only :  spliceosome mutations, including SF3B1, SRSF2 and 
U2AF1 mutations (by  [CONTACT_362236]) or ring sideroblasts .
Absence of the following :
Arm F only :  splic eosome mutations (by  [CONTACT_362236]) and ring ring 
sideroblasts
≥ 18 years of age with life expectancy  of ≥12 weeks.
Able to provide informed consent and be willing to sign an informed consent form.
Eastern Cooperative Oncology  Group (ECOG) performance status of 0, 1 or 2
(Appendix D ).
Protocol CP14B019, Amendment 13
Page 41of 90Evidence for acceptable organ function ≤ 14 days of study  registration as evidenced 
by [CONTACT_716]:
SGOT (AST) 2.5 x upper limit of normal (ULN) (or [ADDRESS_451351] if in the investigator’s 
opi[INVESTIGATOR_362199])
SGPT (AL T) ≤2.5 x upper limit of normal (UL N) (or ≤5 x UL N if in the 
investigator’s opi[INVESTIGATOR_362199])
Total bilirubin ≤3.0 mg/dL (or direct bilirubin <1 mg/dL ).
Creatinine ≤3.0 mg/dL .
Absolute neutrophil count ≥1000/µL (this requirement not needed for Arm D).
Platelet count ≥50,000/µL (this requirement not needed for Arm D).
Females of childbearing potential must have a negative pregnancy  test ≤ 7days prior 
toregistration, unless they  are surgically  sterile (i.e., hy sterec tomy ), OR 
postmenopausal (FSH >30 U/mL ).
Females of childbearing potential must agree to take appropriate precautions to avoid 
pregnancy  (with at least 99% certainty ) from screening through end of study . 
Permitted methods for preventing pregnancy  must be communicated to study  subjects 
and their understanding confirmed .
Males must agree to take appropriate precautions to avoid fathering a child (with at 
least 99% certainty ) from screening through follow -up. Permitted methods for 
preventing pregnancy  should be communicated to the subjects and their understanding
confirmed .
3.2. Exclusion Criteria
Females who are pregnant or are currently  breastfeeding .
Any chemotherapy  (e.g., hy droxy urea), immunomodulatory  drug therapy  (e.g., 
thalidomide), immunosuppressive therap y, corticosteroids > 30 mg/day  prednisone or 
equivalent, growth factor treatment (e.g., ery thropoietin) or JAK inhibitor therapy
 ≤
14 day s prior to 
registration.
Subjects with another active malignancy . Note: Patients with early  stage squamous 
cell carcinoma of the skin, basal cell carcinoma of the skin or cervical intraepi[INVESTIGATOR_362200]
.
Known positiv e status for HI V.
Protocol CP14B019, Amendment 13
Page 42of 90Any unresolved toxicity  greater or equal to Grade 2 from previous anticancer therapy , 
except for stable chronic toxicities not expected to resolve .
Incomplete recovery  from any  prior surgical procedures or had major surgery  ≤ 4 
weeks prio r to 
registration, excluding the placement of vascular access and other 
minor surgical procedures .
Presence of acute active infection requiring antibiotics .
Uncontrolled intercurrent illness or any  concurrent condition that, in the I nvestigator’s 
opi[INVESTIGATOR_1649] , would jeopardize the safety  of the patient or compliance with the protoco l.
Protocol CP14B019, Amendment [ADDRESS_451352] be performed within 3 day s of the day  indicated on the Visit Schedule (except for screening) .
Table 3: Test Schedule : Core Phase = Cycle 1 –Cycle 9; Extension Phase = Cycle 10 and Beyond
Assessment Screening 
(≤14 days 
Prior to 
registration)≤[ADDRESS_451353] 2 
cycles End of 
Cycle 3 End of 
Cycle 9Every Cycle 
in extension 
phase prior to 
infusion 
(Cycles 10 
and beyond)1At study 
completion or 
early 
term ination 
(± 1 week)2Event Monitoring
Every 3 m o until 
PD or subsequent 
treatm ent for MF
Every 6m o after 
PD or subsequent 
treatm ent for 
MF14
Physic al examination including 
weight(height at screening)3,4X X X X
Physical examination for 
hepatomegaly and 
splenomegaly3,4X X X X
Transfusion Assessment X X
Record adverse events4X X X X X
Record concomitant medication X X X
ECOG performance status 
(Appendix D )4X X X X
12-lead ECG X
Chest x -ray X
Serum pregnancy test4,5X X X
Abdominal Ultrasound6X
Urinalysis7X X X
Protocol CP14B019, Amendment 13
Page 44of 90Assessment Screening 
(≤14 days 
Prior to 
registration)≤[ADDRESS_451354] 2 
cycles End of 
Cycle 3 End of 
Cycle 9Every Cycle 
in extension 
phase prior to 
infusion 
(Cycles 10 
and beyond)1At study 
completion or 
early 
term ination 
(± 1 week)2Event Monitoring
Every 3 m o until 
PD or subsequent 
treatm ent for MF
Every 6m o after 
PD or subsequent 
treatm ent for 
MF14
Temperature and vital signs 8X X X X X
Serum chemistry,4,9X X X X X X
Serum calcium, phosphorus, 
magnesium, total proteinX X X X
CBC,4,10X X X X X X
Peripheral blood smear4X X X X
Serum Epo level X X X
International Working Group 
(IWG) Assessment of response4X X
INR (or PT) and aPTT74X X
Bone marrow  biopsy and aspi[INVESTIGATOR_362201]2 
V617F studies11X12X12,13
Follow -up for survival and 
disease status and information of 
subsequent treatment for MF 14X
R Samples may be used by [CONTACT_362237]2V617F allele burden measurement, plasma cytokine 
analysis and other tests that are deemed insightful.
CBC =complete blood count
1In cas e of interruption, a cycle will be 3 months while treatment is held. 
2For all patients w ho did not experience a treatment emergent abnormality in liver function tests (LFTs), defined as any grade abnormality in patients with 
normal value at baseline or a ny higher grade shift from baseline in patients with an abnormal baseline , or value more than 2x baseline if baseline was G rade ≥ 3,
or hepatic adverse events are 
present at imetelstat discontinuation, obtain LFT follow -up until [ADDRESS_451355] schedule (see Section 4for details) until resolution to at least base line grade or less than 2x
baseline value if baseline was Grade ≥ [ADDRESS_451356] cycle will be until the resolution is confirmed.
3Screening physical examination should include the evaluation of head, eye, ear, nose, and throat (HEENT), cardiovascular, der matologic al, musculoskeletal, 
respi[INVESTIGATOR_696], gastrointestinal, and neurological systems.  Changes from baseline abnormalities should be recorded at each subs equent physical examination.  
New or w orsened abnormalities should be recorded as adverse events if appropriat e.  As part of tumor assessment, physical examinations should also include 
the evaluation of the presence and degree of enlarged lymph nodes, hepatomegaly, and splenomegaly.
4If screening assessment was performed within 7 days prior to dosing Day 1 Cycle 1 assessment does not need to be repeated, and the screening assessment will 
serve as baseline.
5All women of childbearing potential (including those who have had a tubal ligation).  For all other women, documentation must be present in the medical 
histor y.
6In addition to baseline abdominal ultrasound, a Doppler ultrasound of abdomen w ill be performed post baseline only as clinically indi cated at the discretion of 
the investigator. The ultrasound w ill assess status of hepatobiliary architecture, which in cludes detection of any gross liver abnormalities; results will be 
compared to the baseline scan.
7Urinalysis to include blood, leukocytes, glucose, protein, pH, specific gravity, ketones, and nitrates.
8Vital signs will include measurements of temperatu re, heart rate, and systolic and diastolic blood pressure.
9Serum chemistries include sodium, potassium, BUN, creatinine, total and direct bilirubin, albumin, ALT, AST, alkaline phospha tase, LDH , and serum ferritin .
In the event of new onset treatment eme rgent total bilirubin of Grade [ADDRESS_451357] be repeated w eekly in patien ts with treatment
-emergent ANC ≤1.0 x 109/L or platelet count< 75x 109/L. CBC includes hemoglobin, platelet count, 
WBC count, and absolute neutrophil count (ANC). 
11Ifbone marrow  biopsy and aspi[INVESTIGATOR_337] w ith cytogenetics and JAK2 V617F studies were performed as standard of care < 30 days prior to the patient signing 
consent procedure need not be repeated. 
12Need to be submitted for central review .  See Section 17for details.
13Only in patients achieving CI, PR or CR per IWG -MRT criteria (See Section 11) for Arms A, B,C, E, F and G, and for patients achieving <5% peripheral blood 
blast percentage, for Arm D. The bone marrow  examination can be performed earlier if patients were to achieve responses e
arlier or per investigator 
discretion.  For the extension phase, only perform as clinically indicated.
14Follow -up for survival status, disease follow-up status, notice of first relapse or progression in event monitoring phase, notice of first subsequent treatment and 
notice of new primary malignancy.  Patients will be initially followed every 3 months (±7 days) after study completion or early treatment termination until 
progressive disease or subsequent treatment for MF. Patients will then be followed ev ery 6 months (±7 days) . Follow -up during the Event Monitoring Phase 
can be completed via telephone call. The Event Monitoring Phase of the study will be considered complete once the last patient has completed study 
treatment.
Protocol CP14B019, Amendment 13
Page 47of 905. GROUPI[INVESTIGATOR_362202] S
All study  arms (A, B, C, D, E, F, and G) are now permanently  closed to enrollment .
6. REGISTRATION/RANDOMI ZATION PROCEDURES
6.1. Registration Procedures
1.To register a patient, access the Mayo Clinic Cancer Center (MCCC) web page and enter 
the registration/randomization application.  The   registration/randomization application 
is available 24 hours a day, 7 day s a week.  Back up and/or sy stem support contact 
[CONTACT_15920].  I f unable to access the Web site, call the MCCC 
Registration Office at between the hours of 8 a.m. and 4:30 p.m. Central 
Time (Monday  through Friday ).
The instructions for the registration/randomization application are available on the 
MCCC web page (http://hsrwww.may o.edu/ccs/training) and detail the process for 
completing and confirming patient registration.  Prior to initiation of protocol treatment, 
this process must be completed in its entirety  and a MCCC subject I D number must be 
available as noted in the instructions.  I t is the responsibility  of the individual registering 
the patient to confirm the process has been successfully  completed prior to release of the 
study  agent.  Patient registration via the registration/randomi zation application can be 
confirmed in any  of the following way s:
Contact [CONTACT_362238], the MCCC Registration Office staff can access the information from the 
centralized database and con firm the registration.
Refer to “I nstructions for Remote Registration” in section “Finding/Display ing 
Information about A Registered Subject.”
2.Documentation of I RB approval must be on file in the Registration Office before an 
investigator may  register any  patients.
In addition to submitting initial I RB approval documents, ongoing I RB approval 
documentation must be on file (no less than annually ) at the Registration Office (fax: 
.  If the necessary  documentation is not submitted in advance of at tempting 
patient registration, the registration will not be accepted and the patient may  not be 
enrolled in the protocol until the situation is resolved.
When the study  has been permanently  closed to patient enrollment, submission of annual 
IRB approvals t o the Registration Office is no longer necessary .

Protocol CP14B019, Amendment 13
Page 48of 903.Prior to accepting the registration, the registration/randomization application will verify  
the following:
IRB approval at the registering institution
Patient eligibility
Existence of a signed consent form
Existence of a signed authorization for use and disclosure of protected health 
information (U.S.A. institutions only ) [delete parenthetical expression (only ) when 
not applicable, i.e. no non -[LOCATION_003] participants]
4.Treatment on this protocol must commence at Mayo Clinic [COMPANY_002]ster under the 
supervision of a hematologist .
5.Treatment cannot begin prior to registration and must begin 7 day s after registration.
6.Pretreatment tests/procedures (see Section 4) must be completed within the guidelines 
specified on the test schedule.
7.All required baseline sy mptoms (see Section 10.6) must be documented and graded.
8.Study  drug is available on site .
7. PROTOCOL TREATMENT
7.1. Treatment Schedule 
7.1.1. Imet elstat Treatment
This is a single center, open -
label study  of imetelstat in patients with I ntermediate -2 or high risk 
PMF /post-ET/PV MF (Arms A, B , C, E and F ) or blast -phase MF (Arm D only )or spliceosome -
mutated (or with ring sideroblasts) MDS/MPN (Arm G only).
Imetelstat will be administered as a 2 -hour I V infusion (± 10 minutes).  The current weight will 
be used to calculate the dose of imetelstat.  All patients must be premedicated prior to imetelstat 
administration. 
As of 22January 2014, all arms ar e permanently  closed to accrual .
Protocol CP14B019, Amendment 13
Page 49of [IP_ADDRESS]. Arm A Treatment Schedule
(Arm A permanently closed to accrual)
Agent Dose Route Day Cycle (ReRx) ±3 
days1
Imetelstat 9.4 mg/kg IV as [ADDRESS_451358] be tolerating the cu rrent 
dose level w ithout significant toxicity.  Increase in dosing frequency is only allowed after Cycle 6.  The cycle 
length will be 21 -28 days.  If the dosing frequency is increased to once weekly, the cycle length will remain 21 
days.  If the dosing fre quency is increased to once every 2 weeks, the cycle length will be 28 days.
3For patients w hose response has plateaued for a minimum of 3 months, the dosing frequency may be reduced after 
Cycle 6 and the cycle length will be the length of the dosing inte rval.  For example, if the dosing frequency is 
decreased to once every 3 months, the cycle length will be 84 days. Dosing can also be interrupted until relapse 
and restarted, in such patients, per physician discretion.  In the case of interruption, a cycle will be 3 months while
treatment is held and the patient will restart at the dose level/schedule they were receiving at the time of 
interruption.
[IP_ADDRESS]. Arm B Treatment Schedule
(Arm B permanently closed to accrual)
Induction: Cycle 1
Agent Dose Route Day Cycl e (ReRx) ± 3 days
Imetelstat 9.4 mg/kg IV as 2 hour 
infusion1, 8, 15 Cycle 1 is 21 days
Maintenance: Cycles 2 and beyond1
Agent Dose Route Day Cycle (ReRx) ±3 days
Imetelstat 9.4 mg/kg IV as 2 hour 
infusion12,3Every 21 days (Cycles 2
and beyond)
1Patients may continue to receive imetelstat study treatment for as long as they derive clinical benefit or until study 
end. The study will end when all subjects have discontinued study drug, the last patient enrolled has been treated 
for [ADDRESS_451359] be tolerating the current 
dose level w ithout significant toxicity.  Increase in dosing frequency is only allowed after Cycle 6.  The cycle 
length will be 21 -28 days.  If the dosing frequency is increased to once weekly, the cycle length will remain 21 
days.  If the dosing frequency is increased to once every 2 weeks, the cycle length will be 28 days.
3For patients w hose response has plateaued for a minimum of 3 months, the dosing frequency may be reduced after 
Cycle 6 and th e cycle length will be the length of the dosing interval.  For example, if the dosing frequency is 
decreased to once every 3 months, the cycle length will be 84 days. Dosing can also be interrupted until relapse 
and restarted, in such patients, per physician discretion.  In the case of interruption, a cycle will be 3 months while 
treatment is held and the patient will restart at the dose level/schedule they were receiving at the time of 
interruption.
Protocol CP14B019, Amendment 13
Page 50of [IP_ADDRESS]. Arms C andD Treatment Schedule
(Arms C and D permanent ly closed to accrual)
Agent Dose Route Day Cycle (ReRx) ±3 days1
Imetelstat 9.4 mg/kg IV as [ADDRESS_451360] two cycles, dosing might be increased to either Days 1, 3, 5 or Days 1,
3 every 2 to 4 w eeks, per physician discretion. For patients w hose response has plateaued for a minimum of 3 
months, the dosing frequency may be reduced after C ycle 6 and th e cycle length will be the length of the dosing 
interval.  For example, if the dosing frequency is decreased to once every 3 months, the cycle length will be 84 
days.  Dosing can also be interrupted until relapse and restarted, in such patients, per physician discretion .  In the 
case of interruption, a cycle will be 3 months while treatment is held and the patient will restart at the dose 
level/schedule they were receiving at the time of interruption.
NOTE:  As of Addendum 3, Arm s A, B, and C arepermanentl y closed to accrual.  The 11 
patients slotted to be enrolled in Arm C will now be treated with either the Arm A (if 
spliceosome
-mutated /with ring sideroblasts ) or Arm B (if spliceosome unmutated) treatment 
schedule.
[IP_ADDRESS]. Arm sE and G Treatment Schedule
(Arms E andG permanently closed to accrual)
Induction Cycle 1 and 2 Dosing
Agent Dose Route Day Cycle (ReRx) ±3 days
Imetelstat 7.5mg/kg IV as 2 hour infusion 1 Cycle is 28 days
Maintenance:  Cycles [ADDRESS_451361].
If any  one of the following criteria is met at the end of Cycle 2, then follow the Table 5dosing
schedule below.  I f no criteria are met, follow the instructions below. 
Greater than 75% reduction in leukocy te count
Greater than 75% reduction in platelet count
Greater than 50% reduction in spleen size in patients with baseline palpable 
splenomegaly  of >5 cm
Greater than 2 gm/dL increase in hemoglobin level from baseline without t ransfusions
Protocol CP14B019, Amendment 13
Page 51of 90Table 5: Arms E and G Dosing if Criteria met = Yes 
Agent Dose Route Day Cycle (ReRx) ±3 days
Imetelstat 7.5mg/kg IV as 2 hour infusion 11,2Cycle is 28 days
1In patients who do not achieve CR or PR b y the end of Cycle 4, the frequency of dosing may be increased to every 
week or every two weeks, at the physician’s discretion
2For patients w hose response has plateaued, w ithout signs of further improvement, for a minimum of 3 months, 
dosing frequency ma y be reduced to every 2 to 3 months, or treatment may be interrupted until relapse and 
restarted, at the physician’s discretion .  In the case of interruption, a cycle will be 3 months while treatment is held 
and the patient will restart at the dose level/s chedule they were receiving at the time of interruption.
Criteria met = No
Treat as specified in Arm F (Cy cle 3 will start with Cy cle 1 of Arm F dosing schedule)
[IP_ADDRESS]. Arm F Treatment Schedule
(Arm F permanently closed to accrual)
Induction Cycle 1 and 2 Dosing
Agent Dose Route Day Cycle (ReRx) ±3 days
Imetelstat 9.4 mg/kg IV as 2 hour infusion 1 Cycle is 28 days
Maintenance:  Cycles [ADDRESS_451362].
If any one of the following criteria is met at the end of Cycle 2, then follow the Table 6dosing 
schedule below.  I f no criteria are met, follow the Table 7and Table 8dosing schedule below. 
Greater than 75% reduction in leukocy te count
Greater than 75% reduction in platelet count
Greater than 50% reduction in spleen size in patients with baseline palpable 
splenomegaly  of >5 cm
Greater than 2 gm/dL increase in hemoglobin level from baseline without transfusions
Table 6: Arm F Dosing if Criteria met = Yes
Agent Dose Route Day Cycle (ReRx) ±3 days
Imetelstat 9.4 mg/kg IV as 2 hour infusion 1 Cycle  is 28 days
Protocol CP14B019, Amendment 13
Page 52of 90Table 7: Arm F Dosing if Criteria met = No: Cycles 3 and 4
Agent Dose Route Day Cycle (ReRx) ±3 days
Imetelstat 7.5 mg/kg IV as 2 hour infusion 1 and 31,2Cycle is 28 days
1In patients who do not achieve CR or PR by [CONTACT_42334] 4, the frequency of dosing may be increased to every 
two weeks, at physician ’sdiscretion.
2For patients w hose response has plateaued, w ithout signs of further improvement, for a minimum of 3 months, 
dosing frequency may be reduced to Day 1 every 28 days or D ays 1, 3 every 2 to 3 months, or treatment may be 
interrupted until relapse and restarted, all at the physician’s discretion .  In the case of interruption, a cycle will be 3 
months while treatment is held and the patient will restart at the dose l evel/schedule they were receiving at the time 
of interruption.
Table 8: Criteria met = No: Cycles 5 and beyond
Agent Dose Route Day Cycle (ReRx) ±3 days
Imetelstat 7.5 mg/kg IV as 2 hour infusion 1, 3, and 51, 2Cycleis 28 days
7.2. Pre-Medication
In Phase I  studies, some patients experienced infusion -related reactions to imetelstat, including 
but not restricted to allergy /hypersensitivity  reaction (e.g., rash, fever, urticaria, dy spnea, 
bronchospasm, chills/rigors, my algias, headache, fatigue, nausea and/or vomiting) during or 
within [ADDRESS_451363] administration of imetelstat.  These reactions were usually  mild to 
moder ate and generally  resolved with slowing or interruption of the infusion and with supportive 
care (diphenhy dramine, corticosteroids, and/or I V saline).  The mechanism is not entirely  clear 
but may  involve complement activation. (See Section 8 for the I nfusion reaction guidelines and
Appendix E .)
All patients will require premedication with diphenhy dramine (25 50 mg, PO or I V) and 
hydrocortisone (10 0mg PO or I V) or equi valent before receiving imetelstat.
Protocol CP14B019, Amendment 13
Page 53of 908. DOSAGE MODIFICATION BASED ON ADVERSE EVENTS
8.1. Retreatment Criteria
Subjects may  receive treatment for a maximum of 9 cy cles during the “Core Phase” of the study . 
Subjects may  be allowed to continue therapy  beyond 9 cy cles in an “Extension Phase” of the 
study ifthey do not meet any  of the withdrawal criteria, do not have disease progression and are 
receiving some clinical benefit, at the discretion of the principle investigator. Patients may  
continue to receive imetelstat study  treatment for as long as they  derive clinical benefit or until 
study  end. The study  will end when all subjects have discontinued study  drug, the last patient 
enrolled has been treated for [ADDRESS_451364].
Patients will be evaluated for safety  and efficacy  at the end of each cy cle during both the core and 
extension phases of the study. 
8.2. Dose Reduction
Once the need for dose reduction has be en established (as per Table 11), treatment with 
imetelstat may  be restarted
,after reversal of drug -related toxicity  (as per Table 11) , with one 
level dose reduction , for patients rec eiving treatment every  21 day s (seeTable 10),or an increase 
in dosing interval (using the same drug dose ) in patients receiving the dru g every  week ; in the 
latter instance, dosing frequency  is first increased to every
 two weeks and then toevery  3weeks, 
in case of recurrent toxicity  that requires dose reduction (see Table 9).Once a dose reduction has
been instituted, the dose should not be re -escalated.
Table 9: Dose Reductions
Dose Frequency Action
Once weekly Reduce to once every 2 or once every 4 weeks at same dose level
(dose level might also be decreased per physician discretion per
Table 10)
Once every 2 weeks Reduce to once every 4weeks at same dose level (dose level might 
also be decreased per physician discretion per Table 10)
Once every 3 weeks Reduce one dose level per Table 10
Once every 4 weeks Reduce one dose level per Table 10
Protocol CP14B019, Amendment 13
Page 54of 90Table 10: Dose Levels (Based on Adverse Events in Table 9)
Dose Level Allarms
019.4 mg/kg D1 
-1 7.5 mg/kg D1 
-2 6 mg/kg D1 
1Dose level 0 refers to the starting dose (except Arms E and G).
Table 11: ALERT : Serious Adverse Event (SAE) reporting may be required for some 
adverse ev ents (See Section 10)
ADVERSE EVENT/ 
laboratory test abnormality 
(must be at least possibly related to 
drug to qualify as a dose -modifying 
event)AGENT ACTION1
AT TIME OF RETREATMENT (i.e. imetelstat infusion beyond D ay 1, C ycle 1 )
Absolute neutrophil count (ANC)  <1.0 x 
109/LImetelstat Hold imetelstat.2Restart at the next lower 
dose level (see Section 8.2), once ANC 
recovers to ≥1.0 x 109/L
Platelet count <50 x 109/L Imetelstat Hold imetelstat.2  Restart at the next lower 
dose level (see Section 8.2
), once platelet 
count recovers to ≥ 50 x 109/L.
Absolute neutr ophil count (ANC) <1.5 x 
109/L and also associated with >75% drop 
from ANC recorded at Day 1 of the 
previous cycleImetelstat Hold imetelstat.2  Restart at the next lower 
dose level  (see Section 8.2), once ANC 
recovers to ≥ 1.5 x 109/L
Platelet count <100 x109/L and also 
associated with >75% drop from platelet 
count recorded at Day 1 of the previous 
cycleImetelstat Hold imetelstat.  2Restart at the next lower 
dose level (see Section 8.2), once platelet 
count recovers to > 100 x 109/L.
SGOT (AST) and SGPT (ALT)  ≥ Grade 3 Imetelstat Hold imetelstat.  Restart at the next lower 
dose level see Section 8.2), if recovered to 
Grade 1 or less (or to pre -study baseline).
Total Bilirubin >3.0 mg/dL (or direct 
bilirubin 1 ≥ mg/dL)Imetelstat Hold imetelstat.  Restart at the next lower 
dose level (see Section 8.2), if recovered to 
Grade 1 or l ess (or to pre- study baseline).
Creatinine >3.0 mg/dL Imetelstat Hold imetelstat.  Restart at the next lower 
dose level (see Section 8.2), if recovered to 
Grade 1 or less (or to pre- study baseline).
Protocol CP14B019, Amendment 13
Page 55of 90ADVERSE EVENT/ 
laboratory test abnormality 
(must be at least possibly related to 
drug to qualify as a dose -modifying 
event)AGENT ACTION1
Allergic Re action Grade 2 Imetelstat Hold imetelstat.  Restart at the next lower 
dose level if adverse event reduced to <
Grade 1. Discontinue imetelstat if event 
reoccurs at lower dose.
Allergic Reaction Grade 3 Imetelstat Discontinue imetelstat and go to event 
monitoring per Section 4
Any Grade 33Imetelstat Hold imetelstat.  Restar t at the next lower 
dose level (see Section 8.2), if adverse event 
reduces to <Grade 2.
Any Gr ade 44Hold imetelstat.  Restart at the next lower 
dose level (see Section 8.2), if adverse event 
reduces to <Grade 2.
1Use the following to describe actions in the Action column:
Omit = The current dose(s) f or the specified drug(s) during a cycle is skipped. The patient does not make 
up the omitted dose(s) at a later time
Hold/Delay = The current dose(s) of all drugs during a cycle is delayed. The patient does make up the 
delayed dose(s) w hen the patient me ets the protocol criteria to restart drugs. Hold for maximum of [ADDRESS_451365] principal investigator [INVESTIGATOR_214058].
Discontinue = The specified drug(s) are totally stopped.
2Not required for cohort D.
3Except fatigue, nausea, vomiting, diarrhea and hyperuricemia that persist despi[INVESTIGATOR_362203] -
diarrheals or anti -emetics.  Such toxicity will be taken into account, for dose holding only when it persists despi[INVESTIGATOR_6511]. 
4Except Grade 4 uric acid toxicity. Such toxicity will be taken into account for dose holding only when refractory 
to appropriate treatment.
In addition to any  of the above toxicities, in the event of a drug -related Grade 2 or higher toxicity  
that the patient cannot tolerate or at the discr etion of the I nvestigator, dosing may  be reduced.
8.2.1. Hepatoxicity
Diagnosis of a treatment emergent hepatic adverse event such as hepatitis, jaundice or 
other hepatic AEs or hepatic biochemistry  abnormalities of clinical significance 
should lead to additional monitoring and an evaluation of ongoing benefit- risk with 
imetelstat; dose modification and/or study  treatment termination should be considered 
in such cases and discussed with the medical monitor.  Consider a hepatic 
consultation if indicated. External experts may  also be consulted by  [CONTACT_362239] . 
See Table 11above for dose modifications. All imetelstat dose reductions due to
liver enzy me elevations are permanent.  
Protocol CP14B019, Amendment 13
Page 56of 90Discontinue imetelstat permanently  and enter follow -up if a significant hepatic event, 
including hepatic biochemistry  abnormalities, indicating the potential for severe 
hepatic injury  is observed without a more likely  cause than study  treatment.  Baseline 
liver labora tory abnormalities and clinical presentation should be taken into 
consideration.  Bilirubin should be fractionated and be primarily  conjugated.
For patients who enter hepatic safety  monitoring and follow up after imetelstat discontinuation 
refer to Table 4for details of clinical parameters and duration of follow -up.  
8.3. Infusion Reaction
The guidelines described in Table 12should be followed for managing imetelstat infusion
reactions (See Appendix E ).
Table 12: Guidelines for Managing Infusion Reactions
Infusion Reaction Management Guideline
Grade 1
Mild and transient (e.g., mild flushing, 
rash, pruritis, fever)Evaluat e and manage symptomatically as needed .
May complete infusion if reaction remains mild, with 
stable vital sign s and does not worsen to Grade 2 or 
more .
Grade 2
Moderate (e.g., moderate flushing, rash, 
dyspnea, chest discomfort, hypotension)Stop infusion
Manage symptomatically:
Admin ister diphenhydramine 25 mg and 
dexamethasone 10 mg IV, if required (particularly if 
not recei ved within last 4 hours)
Consider IV fluids, acetaminophen, oxygen, 
bronchodilators etc.
After recove ry, resume infusion at half the previous rate 
for 15 minutes
If no f urther symptoms occur, complete the infusion 
at the full dose rate
If symptoms recur, discontinue imetelstat   
Grade 3
Severe (not rapi[INVESTIGATOR_86025]/or brief 
interruption of infusion; recurrence of 
symptoms following initial improvement; 
hospi[INVESTIGATOR_102340] (e.g., renal impairment, 
pulmonary infiltrates)Stop infusion 
Administer supportive care as indicated
Consider epi[INVESTIGATOR_238], corticosteroids, 
diphenhydramine, IV fluids, acetaminophen, oxygen, 
bronchodilators, vasopressors, etc.
Discontinue imetelstat
Protocol CP14B019, Amendment 13
Page 57of 90Grade 4
Life-threatening (e.g., anaphylaxis, 
angioedema severe hypotension requiring 
vasopressors, respi[INVESTIGATOR_362204] g ventilator support)Stop infusion
Administer supportive care as indicated
Discontinue imetelstat 
9. ANCILLARY TREATMENT/ SUPPORTIVE CARE
Antiemetics may be used at the discretion of the attending phy sician.
Patients should receive full supportive care whil e on this study .  This includes blood 
product support, antibiotic treatment, and treatment of other newly  diagnosed or 
concurrent medical conditions.  All blood products and concomitant medications such 
as antidiarrheals, analgesics, and/or antiemetics rec eived from the first day  of study 
treatment administration until 30 day s after the final dose will be recorded in the 
medical records.
Diarrhea:  This could be managed conservatively  with loperamide.  The 
recommended dose of loperamide is [ADDRESS_451366] ons et, followed by  2 mg every  2-4 
hours until diarrhea free (maximum 16 mg/day ).
In the event of Grade 3 or 4 diarrhea, the following supportive measures are allowed:  
hydration, octreotide, and antidiarrheals.  
If diarrhea is severe (requiring intravenous r ehydration) and/or associated with fever 
or severe neutropenia ( Grade 3 or 4), broad -spectrum antibiotics must be prescribed.  
Patients with severe diarrhea or any  diarrhea associated with severe nausea or 
vomiting should be hospi[INVESTIGATOR_362205].
10. ADVERSE EVENT (AE) R EPORTING AND 
MONITORING
10.1. Safety Parameters and Definitions
Safety  assessments will consist of recording all adverse events (AEs) and serious adverse events 
(SAEs); protocol -specified hema tology  and clinical chemistry  variables; measurement of 
protocol -specified vital signs; and the results from other protocol -specified tests that are deemed 
critical to the safety  evaluation of imetelstat.
Janssen Research & Development or its designee is responsible for reporting relevant SAEs to 
the Competent Authority , other applicable regulatory  authorities, and participating I nvestigators, 
in accordance with I CH guidelines, FDA regulations, European Clinical Trials Directive 
(Directive 2001/20/EC ), and/ or local regulatory  requirements.
Protocol CP14B019, Amendment 13
Page 58of 90Janssen Research & Development or its designee is responsible for reporting unexpected fatal or 
life-threatening events associated with the use of the study  drug to the regulatory  agencies and 
competent authorities by  [CONTACT_144530] 7 calendar day s after being notified of the event. 
Janssen Research & Development or its designee will report other relevant SAEs associated with 
the use of the study  medication to the regulatory  agencies and competent authorities by  [CONTACT_362240] [ADDRESS_451367] discontinued imetelstat 
treatment, an AE is defined as an unfavorable and unintended sign, sy mptom, or disease 
occurring during the follow -up period or temporally  associated with a protocol -imposed 
intervention, regardless of attribution.
This includes the following:
AEs not previously  observed in the patient that emerge during the protocol -specified 
AE reporting period, including signs or sy mptoms associated with MF that were not 
present prior to the AE reporting period (see Section 10.2.1)
Complications that occur as a result of protocol
-mandated interventions (e.g., invasive 
procedures such as biopsies)
AEs that occur prior to assignment of study  treatment that are related to a 
protocol -mandated intervention (e.g., invasive procedures such as biopsies, 
medication washout, or no treatment run -in)
Preexisting medical conditions, judged by  [CONTACT_941] I nvestig ator to have worsened in 
severity  or frequency  or changed in character during the protocol -specified AE 
reporting period
10.1.2. Serious Adverse Event
An SAE is any  AE that is any  of the following:
Fatal (i.e., the AE actually causes or leads to death)
Life threat ening (i.e., the AE, in the view of the I nvestigator, places the patient at 
immediate risk of death)
Requires or prolongs inpatient hospi[INVESTIGATOR_059]
Results in persistent or significant disability /incapacity  (i.e., the AE results in 
substantial disruption of the patient’s ability  to conduct normal life functions)
Protocol CP14B019, Amendment 13
Page 59of 90A congenital anomaly /birth defect in a neonate/infant born to a mother exposed to the 
investigational product(s)
Considered a significant medical event by  [CONTACT_941] I nvestigator (i.e., may jeopardize the 
patient or may  require medical/surgical intervention to prevent one of the outcomes 
listed above)
All AEs that do not meet any  of the criteria for serious should be regarded as non-serious AEs .
The terms “severe” and “serious” are not sy nonymous.  Severity refers to the intensity  of an AE 
(as in mild, moderate, or severe pain); the event itself may  be of relatively  minor medical 
significance (such as severe headache).  “Serious” is a regulatory  definition and is based on 
patient or event outcome or action c riteria usually  associated with events that pose a threat to a 
patient’s life or vital functions.  Seriousness (not severity ) serves as the guide for defining 
regulatory  reporting obligations.
Severity and seriousness should be independently  assessed when recording AEs and SAEs on the 
eCRF.
10.2. Methods and Timing for Capturing and Assessing Safety Parameters
The I nvestigator is responsible for ensuring that all AEs and SAEs (as defined in Section 10.1)
are recorded on the eCRF and reported to the Sponsor in accordance with protocol instructions.
10.2.1. Adverse Event Reporting Period
After initiation of imetelstat, all AEs and SAEs regardless of attribution will be collected until 
30days following the last administration of s tudy treatment or at study  complet ion/early  
treatment termination. After this period, I
nvestigators should report only SAEs that are felt to be 
related to study  treatment, unless the patient is continuing on study  for additional hepatic safety  
monitoring a s defined in Section [IP_ADDRESS].
For patients who have discontinued imetelstat and are undergoing extended hepatic safety  
follow -up due to ongoing liver biochemistry  abnormalities or hepatic AEs, monitoring and da ta 
collection, including all
AEs and SAEs regardless of attribution, should continue as defined in 
Table 4.
See Section 10.[ADDRESS_451368] -study  AE reporting.
Protocol CP14B019, Amendment 13
Page 61of 90To ensure consistency  of causality  assessments, the I nvestigator should apply  the following 
general guidelines:
Table 14: Causal Attribution Guidance
Is the AE/SAE suspected to be cau
sed by [CONTACT_362241], evidence, science -
based rationales, and clinical judgm ent?
YES The temporal relationship of the AE/SAE to investigational product administration makes a causal 
relationship possible, AND other drugs, ther apeutic interventions or underlying conditions do not 
provide sufficient explanation for the AE/SAE.
NO The temporal relationship of the AE/SAE to investigational product administration makes a causal 
relationship unlikely, OR other drugs, therapeutic int erventions or underlying conditions provide a 
sufficient explanation for the AE/SAE.
Note: In the absence of another explanation, such as acute infection, repeated courses of chemotherapy 
(modification), gastrointestinal bleeding, hemolysis, and so forth. It is recommended that the [ADDRESS_451369] med ical terminology /concepts when recording AEs on the 
eCRF.  Avoid colloquialisms and abbreviations.
A separate Adverse Event eCRF should be used for each medical concept that needs to be 
recorded.
[IP_ADDRESS]. Diagnosis Versus Signs and Symptoms
If known, a diagnosis sh ould be recorded on the eCRF rather than individual signs and sy mptoms 
(e.g., record only  liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases).  However, if a constellation of signs and/or sy mptoms cannot be medically  
characterized as a single diagnosis or sy ndrome at the time of reporting, each individual event 
should be recorded as an AE on a separate eCRF.  I f a diagnosis is subsequently  established, it 
should be reported to Janssen Research & Development per the CRF Completion Guidelines.
[IP_ADDRESS]. Adverse Events Occurring Secondary to Other Events
In general, AEs occurring secondary  to other events (e.g., cascade events or clinical sequelae) 
should be identified by  [CONTACT_5252].  For example, if severe diarrhea is known t o have 
resulted in dehy dration, it is sufficient to record only  diarrhea as an AE on the eCRF.
However, medically  significant AEs occurring secondary  to an initiating event that are separated 
in time should be recorded as independent events on the eCRF.  F or example, if a severe 
gastrointestinal hemorrhage leads to renal failure, both events should be recorded separately  on 
the eCRF.
Protocol CP14B019, Amendment 13
Page 62of 9010.3.1.3. Persistent or Recurrent Adverse Events
A persistent AE is one that extends continuously , without resolution between patient e valuation 
timepoints.  Such events should only  be recorded once in the eCRF unless their severity  
increases.  I f a persistent AE becomes more severe, it should be recorded again on the Adverse 
Event eCRF.
A recurrent AE is one that occurs and resolves betw een patient evaluation timepoints and 
subsequently  recurs.  All recurrent AEs should be recorded on Adverse Event eCRF.
[IP_ADDRESS]. Abnormal Laboratory Values
Only  clinically  significant laboratory  abnormalities that require active management will be 
recorded as AEs o n the eCRF (e.g., abnormalities that require study drug dose modification, 
discontinuation of study  treatment, more frequent follow -up assessments, further diagnostic 
investigation, etc.).
If the clinically  significant laboratory  abnormality  is a sign of a disease or sy ndrome (e.g., 
alkaline phosphatase and bilirubin 5 ULN associated with cholecy stitis), only  the diagnosis 
(e.g., cholecy stitis) needs to be recorded on the Adverse Event eCRF.
If the clinically  significant laboratory  abnormality  is not a si gn of a disease or sy ndrome, the 
abnormality  itself should be recorded as an AE on the eCRF.  I f the laboratory  abnormality  can 
be characterized by  a precise clinical term, the clinical term should be recorded as the AE.  For 
example, an elevated serum pot assium level of 7.0 mEq/L  should be recorded as “hy perkalemia”.
Observations of the same clinically  significant laboratory  abnormality  from visit to visit should 
not be repeatedly  recorded as AEs or SAEs on the eCRF, unless their severity , seriousness, or 
etiology  changes.
[IP_ADDRESS]. Deaths
All deaths that occur during the protocol -specified AE reporting period (see Section 10.1.2),
regardless of attribution, will be recorded on an eCRF and expeditiously  reported to the Spon sor. 
This includes death attributed to progression of MF.
If the death is attributed to progression of MF, record “My lefibrosis 
progression” as the SAE 
term on the SAE Report Form.
When recording a death on an eCRF or SAE Report Form, the event or conditi on that caused or 
contributed to the fatal outcome should be recorded as the single medical concept.  I f the cause of 
death is unknown and cannot be ascertained at the time of reporting, record “Unexplained 
Death .”
[IP_ADDRESS]. Preexisting Medical Conditions
A preexist ing medical condition should be recorded as an AE only ifthe frequency , severity , or 
character of the condition worsens during the study .  When recording such events on an Adverse 
Protocol CP14B019, Amendment 13
Page 63of 90Event eCRF, it is important to convey  the concept that the preexisting cond ition has changed by  
[CONTACT_9672] (e.g., “more frequent headaches”).
[IP_ADDRESS]. Worsening of MF
Worsening of and/or progression of MF should not routinely  be recorded as an AE or SAE if not 
resulting in death. These data will be captured as effica cy assessment data. However worsening 
and/or progression of MF should be recorded an SAE if fatal (see Section 10.1.2 or if the
investigator assesses the disease progression to be related to imetelstat.   
[IP_ADDRESS]. Hospit alization, Prolonged Hospi[INVESTIGATOR_059], or Surgery
Any AE that results in hospi[INVESTIGATOR_362206].
There are some hospi[INVESTIGATOR_362207].  These scenarios include a planned hospi[INVESTIGATOR_362208]:
Perform an efficacy  measurement for the study
Undergo a diagnostic or elective surgical p rocedure for a preexisting medical 
condition that has not changed
Receive scheduled therapy  for the target disease of the study
[IP_ADDRESS]. Pregnancy
If a female patient becomes pregnant while receiving investigational therapy  or within [ADDRESS_451370] s be classified as serious (as the 
Sponsor considers these medically  significant), recorded on a Serious Adverse Event Form (SAE 
Form) and expeditiously  reported to 
the Sponsor .
Any congenital anomaly /birth defect in a child born to a female patient or female partner of a 
male patient exposed to the investigational product should be recorded and reported as an SAE.
[IP_ADDRESS]. Hepatic Adverse Events and Abnormal Liver Biochemistries
Abnormal liver biochemistries and hepatic AEs should be reported p er routine protocol reporting 
procedures on the relevant eCRF ( e.g.,Adverse Event eCRF, chemistry  CRF ).
In the event a patient has discontinued imetelstat, but qualifies for the extended hepatic safety  
follow -up due to ongoing liver biochemistry abnormali ties or hepatic AEs at the study  
Protocol CP14B019, Amendment 13
Page 64of 90completion/early  treatment termination visit, monitoring and data entry  into the relevant eCRF 
(i.e., adverse event, laboratory  data, and concomitant medications) should continue per the 
guidelines in Table 4.  These assessments should occur regardless of the initiation of alternate
MF treatments.
10.4. Expedited Reporting Requirements for Serious Adverse Events
10.4.1. Reporting Requirements for Fatal/Life Threatening SAEs Related to 
Investigation al Product
Any life-threatening (i.e., imminent risk of death) or fatal AE that is attributed by  [CONTACT_941] I nvestigator 
to the investigational product will be telephoned to the Medical Monitor immediately , followed 
by [CONTACT_362242] 24 hours as described in 
Section 10.3.
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_362243] o
n the Contact I nformation 
page(s), which will be provided as a separate document. 
10.4.2. Reporting Requirements for All SAEs
All serious adverse events occurring during the study  must be reported to the appropriate S ponsor 
contact [CONTACT_300480] -site personnel within [ADDRESS_451371] be completed and signed by a phy sician from the study  site, 
and transmitted to the sponsor w ithin 24 hours. The initial and follow -up reports of a serious 
adverse event should be made by  [CONTACT_6972] (fax) .
All serious adverse events that have not resolved by  [CONTACT_2054] , or that have not 
resolved upon discontinuation of the s ubject's participation in the study , must be followed until 
any of the following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event may  be attributed to agents other than the stu dy treatment or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information may be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -
up after demonstration 
of due diligence with follow -up ef forts)
Protocol CP14B019, Amendment 13
Page 65of 9010.5. Type and Duration of Follow -Up of Patients after Adverse Events
The I nvestigator should follow all unresolved AEs and SAEs until the events are resolved or 
stabilized, are determined to be irreversible by  [CONTACT_941] I nvestigator, the pati ent initiates alternate MF 
treatment (unless undergoing extended hepatic safety  follow -up), the patient is lost to follow -up, 
or it has been determined that the study  treatment is not the cause of the AE/SAE.  Resolution of 
AEs and SAEs (with dates) should be documented on the Adverse Event eCRF and in the 
patient’s medical record to facilitate source data verification (SDV).
The Sponsor or its designee may  follow up by  [CONTACT_756], fax, electronic mail, and/or a 
monitoring visit to obtain additional case det ails deemed necessary  to appropriately  evaluate the 
SAE report (e.g., hospi[INVESTIGATOR_44458] , consultant report, or autopsy  report).
10.6. Post-Study Adverse Events
For patients who discontinue the study  and are not in the extended hepatic safety  follow -up, the 
Investigator should report any  death 
or other SAE occurring bey ond [ADDRESS_451372] administration of study  drug, per the 
guidelines in Section [IP_ADDRESS].
The I nvestigator should also, upon becoming aware of, report t
he development of cancer or of a 
congenital anomaly  in a subsequently  conceived offspring of a patient that participated in this 
study .  
The I nvestigator should report these events on an SAE Form to the Sponsor as described in 
Section 10.3 above.
Protocol CP14B019, Amendment 13
Page 66of 9011. TREATMENT EVALUATION
11.1. Myelofibrosis
Table 15: Revised International Working Group for Myeloproliferative Neoplasms 
Research and Treatment (IWG -MRT) and European LeukemiaNet (ELN) 
response criteria for myelofibrosis.
Response
categoriesRequired criteria (for all response categories, benefit must last for 
≥12 weeks in order to 
qualify as a response)
Complete
Remission
(CR)Bone marrow:1Age-adjusted normocellularity; <5% blasts; ≤Grade 1 myelofibrosis2, AND
Peripheral blood: Hemoglobin ≥100 g/L and <UNL; Neutrophil count ≥1 x 109/L and <UNL;
Platelet count ≥100 x 109/L and <UN L; <2% immature myeloid cells3, AND
Clinical: Resolution of disease symptoms; Spleen and liver not palpable; N o evidence of EMH
Partial
Remission
(PR)Peripheral blood: Hemoglobin ≥100 g/L and <UNL; Neutrophil count ≥1 x 109/L and <UNL;
Platelet count ≥ 100 x 109/L and <UNL; <2% immature myeloid cells3, AND
Clinical: Resolution of disease symptoms; Spleen and liv er not palpable; No evidence of EMH , 
OR
Bone marrow:1Age-adjusted normocellularity; <5% blasts; ≤Grade 1 myelofibrosis2, AND
Peripheral blood: Hemoglobin ≥85 but <100 g/L and <UNL; Neutrophil count ≥1 x 109/L and 
<UNL;
Platelet count ≥50 but <100 x 109/Land <UNL; <2% immature myeloid cells3, AND
Clinical: Resolution of disease symptoms; Spleen and liver not palpable; No evidence of EMH
Clinical
Improvement
(CI)The achievement of anemia, spleen or symptoms response without progressive disease or
increase in severity of anemia, thrombocytopenia or neutropenia4
Anemia
responseTransfusion- independent patients: a ≥20 g/L increase in hemoglobin level5
Transfusion- dependent patients: becoming transfusion- independent6
Spleen
response7A baseline splenomegaly that is palpable at 5 -10 cm, below the LCM, becomes not palpable8, 
OR
A baseline splenomegaly that is palpable at >10 cm, below the LCM, decreases by ≥50%8
A baseline splenomegaly that is palpable at <[ADDRESS_451373] showing ≥35% spleen volume reduction is recommended (but not 
required)
Protocol CP14B019, Amendment 13
Page 67of 90Response
categoriesRequired criteria (for all response categories, benefit must last for ≥ 12 weeks in order to 
qualify as a response)
Progressiv e
disease9Appearance of a new splenomegaly that is palpable at least 5 cm below the LCM, OR
A ≥100% increase in palpable distance, below LCM, for baseline splenomegaly of 5 to 10 cm, 
OR
A 50% increase in palpable distance, below LCM, for baseline splenome galy of >[ADDRESS_451374] count of ≥20%, OR
A peripheral blood blast content of ≥20% associated with an absolute blast count of ≥1 x 109/L 
thatlasts for at least 2weeks
Stable disease Belonging to none of the above listed response categories
Relapse No longer meeting criteria for at least CI after achieving CR, PR or CI, OR
Loss of anemia response persisting for at least one month, OR
Loss of spleen response persisting for at least one month
Key: CT = computed tomography; EMH = extramedullary hematopoiesis (no evidence of EMH implies the absence of 
pathology -or imaging study -proven non -hepatosplenic EMH) ; LCM = left costal margin; MRI = magnetic resonance 
imaging; UNL = upper normal limit
1Baseline a nd post -treatment bone marrow slides are to be stained at the same time and interpreted at one sitting by 
a central review  process. Cytogenetic and molecular responses are not required for CR assignment.
2Grading of myelofibrosis is according to the Europ ean classification ( Thiele et al. Haematologica 2005;90:1128 ) . 
It is underscored that the consensus definition of “a complete remission bone marrow” is to be used only in those 
patients where all other criteria, including resolution of leukoerythroblastos is, are met. It should also be noted that 
it was a particularly difficult task for the working group to reach a consensus regarding what represents a complete 
histological remission.
3Immature myeloid cells constitute blasts + promyelocytes + myelocytes + metamyelocytes + nucleated red blood 
cells. In splenectomized patients, <5% immature myeloid cells is allowed.
4See table 1 5for definitions of anemia response, spleen response and progressive disease. Increase in severity of 
anemia constitutes the occu rrence of new transfusion dependency or a ≥20 g/L decrease in hemoglobin level from 
pre-treatment baseline that lasts for at least 12 weeks. Increase in severity of thrombocytopenia or neutropenia is 
defined as a 2 -grade decline, from pre -treatment baselin e, in platelet count or absolute neutrophil count, according 
to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In addition, assignment to clinical 
improvement (CI) requires a minimum platelet count of ≥25,000 x 109/L and absolute neutr ophil count of ≥0.5 x 
109/L.
5Applicable only to patients with baseline hemoglobin of <100 g/L. In patients not meeting the strict criteria for 
transfusion -dependency at the time of study enrollment (see below), but have received transfusions within the 
previous month, the pre- transfusion hemoglobin level should be used as the baseline
6Transfusion dependency before study enrollment is defined as transfusions of at least 6 units of packed red blood 
cells (PRBC), in the 12 w eeks prior to study enrollment, for a hemoglobin level of <85 g/L, in the absence of 
bleeding or treatment -induced anemia. In addition, the most recent transfusion epi[INVESTIGATOR_320862] 
28 days prior to study enrollment. Response in transfusion dependent patients requires a bsence of any PRBC 
transfusions during any consecutive “rolling” 12 -week interval during the treatment phase, capped by a hemoglobin 
level of ≥85 g/L.
7In splenectomized patients, palpable hepatomegaly is substituted with the same measurement strategy
8Confirmation of spleen or liver responses by [CONTACT_362244] (but not required), where a ≥35% 
reduction in spleen or liver volume, assessed by [CONTACT_9252] (MRI) or computed tomography 
(CT), is required for confirmation. Further more, a≥35% volume reduction in the spleen or liver, by [CONTACT_68454], 
constitutes a response regardless of what is reported with physical examination.
Symptoms are evaluated by [CONTACT_362245] 
(MPN -SAF TSS). The MPN -SAF TSS is assessed by [CONTACT_362246], concentration, 
Protocol CP14B019, Amendment 13
Page 68of 90early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Scoring is 
from 0 (absent/as good as it can be) to 10 (w orst imaginable/as bad as it can be) for each item. The MPN -SAF 
TSS is the summation of all the individual scores (0 -to-100 scale). Symptoms response requires ≥50% reduction in 
the MPN-SAF TSS.
9Confirmation by [CONTACT_362247] (but not required) to confirm progressive disease assignment for 
splenomegaly, where a ≥25% increase in spleen volume from baseline is required for confirmation. Baseline 
values for both physical examination and imaging studies refer to pre -treatment baseline and not to post -treatment 
measurements.
11.2. MDS
The I nternational Working Group response assessm ent as reported by  [CONTACT_248286]. ( 2006) will 
be utilized.
Table 16: Definition of Disease Response in MDS:
Category Response Criteria 
Complete Remission (CR) Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines1
Persistent dysplasia will be noted1,2
Peripheral blood3
Hgb ≥ 11 g/dL
Platelets ≥ 100 x 109/L 
Neutrophils ≥ 1.0 x 109/L2
Blasts 0%
Partial Remission ( PR) All CR criteria if abnormal before treatment except:
Bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%
Cellularity and morphology not relevant
Stable Disease (SD) Failure to achieve at least PR, but no evidence of progression for > 8 w eeks
Failure (FAIL) Death during treatment or disease progression characterized by [CONTACT_27749], increase in percentage of bone marrow blasts, or progression to a 
more advanced MDS FAB subtype than pretreatment
Relapse after CR or PR At least 1 of the following:
Return to pretreatment bone marrow blast percentage
Decrement of ≥ 50% from maximum remission/response levels in 
granulocytes or platelets
Reduction in Hgb concentration by ≥ 1.5 g/dL or transfusion dependence
Protocol CP14B019, Amendment 13
Page 69of 90Category Response Criteria 
Disease Progression (PD) For patients with:
Less than 5% blasts: ≥ 50% increase in blasts to > 5% blasts
5%-10% blasts: ≥ 50% increase to > 10% blasts
10%- 20% blasts: ≥ 50% increase to > 20% blasts
20%- 30% blasts: ≥ 50% increase to > 30% blasts
Any of the following:
At least 50% decrement from maximum remission/response in 
granulocytes or platelets
Reduction in Hgb by ≥ 2 g/dL
Transfusion dependence
1Dysplastic changes should consider the normal range of dysplastic changes (modification).
2Modification to IWG response criteria.
3In some circumstances, protocol therapy may require the initiation of further treatment ( e.g., consolidation, 
maintenance) before the 4 -week period. Such patients can be included in the response category into which they fit 
at the time the therapy is started. Transient cytopenias during repeated chemotherapy courses should not be 
considered as interrupting durability of response, as long as they recover to the improved counts of the previous 
course.
Table 17: Proposed Modified International Working Group Response Criteria for 
Hematologic Improvement
Hematologic improvement1Response criteria2
Erythroid response (pretreatment, < 
11 g/dL)Hgb increase by ≥1.5 g/dL
Relevant reduction of units of RBC transfusions by [CONTACT_362248] 4 RBC transfusions/8 wk compared with the p retreatment transfusion 
number in the previous 8 wk. Only RBC transfusions given for a Hgb of 
≤9.0 g/dL
pretreatment will count in the RBC transfusion response evaluation2
Platelet response 
(pretreatment, < 100 X 109/L)Absolute increase of ≥30 X109/L for patients starting with >20 x109/L 
platelets
Increase from <20 _X 109/L to >20 X109/L and by [CONTACT_2669] 100%2
Neutrophil response (pretreatment,
<1.0x109/L)At least 100% increase and an absolute increase > 0.5 X_109/L2
Progression or relapse af ter HI3At least 1 of the following:
At least 50% decrement from maximum response levels in granulocytes 
or platelets
Reduction in Hgb by ≥1.5 g/dL
Transfusion dependence
Note: To convert hemoglobin levels from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
Hgb indicates hemoglobin; RBC: red blood cell; HI: hematologic improvement.
1Pretreatment counts averag es of at least 2 measurements (not influenced by [CONTACT_27752]) ≥ 1 w eek apart 
(modification).
2Modification to IWG response criteria.
3In the absence of another explanation, such as acute infection, repeated courses of chemotherapy (modification), 
gastro intestinal bleeding, hemolysis, and so forth. It is recommended that the 2 kinds of erythroid and platelet 
responses be reported overall as w ell as by [CONTACT_27753].
Protocol CP14B019, Amendment 13
Page 70of 9012. DESCRIPTIVE FACTORS
Category  of MF ( see Appendix B ):  Primary  Myelofibrosis vs. Post ET My elofibrosis 
vs. Post PV My elofibrosis vs. blast- phase MF vs MDS/MPN or MDS
DIPSS-plus risk (s ee Appendix A ):  High -risk MF vs. I ntermediate -2 risk MF
13. TREATMENT/FOLLOW –UP DECISION A T EVALUATION OF 
PATIENT
Patients who are CR, PR, CI , or SD will continue treatment per protocol.
Patients will be discontinued from treatment and go to event -monitoring phase per Section 4for
any of the followin g reasons:
Disease progression (Except relapse that occurs during dose interruption).
Leukemic transformation (as per WHO criteria)
Any clinical adverse event, laboratory  abnormality , intercurrent illness or other 
medical condition or situation which occ urs such that continued participation in the 
study  would not be in the best interest of the participant
Hepatotoxicity  criteria for treatment discontinuation (see Section 8.2.1)
Pregnancy
Diagnosis of positive s tatus for HI V or hepatitis B or C
Continued failure to comply  with study  procedures or use of the drug as specified in 
the study  protocol such that continued participation in the study  would not be in the 
best interest of the participant
Withdrawal of cons ent
Initiation of non -protocol therapi[INVESTIGATOR_014]
Administrative decision by  [CONTACT_362249]
A patient is deemed ineligible if after registration, it is determined that at the time of registration, 
the patient did not satisfy  each and every  eligibility  criteria for study  entry .  The patient may  
continue treatment off -protocol at the discretion of the phy sician as long as there are no safety  
concerns, and the patient was properly  registered. The patient will go directly
 to the event -
monitoring phase of the s tudy. 
Protocol CP14B019, Amendment [ADDRESS_451375] -treatment of 5.54 μg/mL .  This confirmed the presence of imetelstat in the 
target tissue, bone marrow, after I V administration to MM patients.
b.Distribution – V dssranged from 41/3 to 71.2 mL /kg at doses of 4.8 to 11.7 mg/kg.
c.Excretion – T 1/2following a single -dose ranged from [ADDRESS_451376] 
following metabolism of the oligonucleotide sequence into smaller fragments.  Based 
on a preliminary  population pharmacokinetic analy sis of 59 patients who received 2-
or 6-hour weekly  IV infusions of imetelstat 0.4 to 11.7 mg/kg (30 −1155 mg) or 
20−240 mg/m2(37.4 −516 mg), the estimated CL  of imetelstat varied by  [CONTACT_362250] 
(body  weight or BSA) and dose. After correcting for body  size, the CL  at a BSA of 
1.86 m2was 0.206 L /hr and total CL  was 0.84 L /hr at a dose of 9.4 mg/kg ( ≈ 380 
mg/m2).
15.1.6. Potential Drug Interactions
To date, no known drug interactions have been identified with imetelstat treatment.
15.1.7. Safety Experience
Refer to S ection 1.3.4 for safety  experience . 
For further details, see the Imetelstat I nvestigator’s Brochure.
15.1.8. Drug Procurement
Imetelstat will be provided free of charge to stud yparticipants by [CONTACT_12945] & 
Development .
15.1.9. Nursing G uidelines
As drug is early  in development, not all side effects can be known at this time. Monitor patients 
carefully  and instruct patient to report any  side effects to the treating phy sician and/or study  team 
immediately .
In Phase I  studies cy topenias (thrombocy topeni a and neutropenia )were the primary  dose -limiting 
side effects especially  when administered with other cy totoxic agents . Monitor CBC 
w/differential closely . Instruct patients in signs and sy mptoms of infection and to report any  
unusual bruising or bleeding to the study  team immediately .
Infusion reactions have been seen and are usually  mild -moderate in nature. These usually  occur 
shortly  after infusion initiation and can occur with subsequent cy cles, despi[INVESTIGATOR_362209]. Have emergenc y medications on hand and administer at the phy sician’s 
discretion (See Section 8.3andAppendix E ).
Patients may  experience prolonged a PTT times. Instruct patients to report any  unusually  
bleeding to study  team immediately .
Protocol CP14B019, Amendment 13
Page 74of 90Gastrointestinal side effects (diarrhea, nausea, vomiting, etc.) have been seen (See Section 9).
Treat sy mptomatically  and monitor for effectiveness.
Fatigue is common.  I nstruct patient in energy  conserving lifesty le.
16. STATISTICAL CONSIDER ATIONS AND METHODOLO GY 
Overview:  This protocol will assess the efficacy  of 
different schedules of i metelstat in six 
cohorts of patients with my elofibrosis (including blast -phase disease in Arm D) and one cohort 
of patients with MDS/MPN or MDS with spliceosome mutations or ring sideroblasts using a 
phase I I study  design in each arm independently .
Descriptive statistics will be used to summarize baseline patient characte ristics, treatment 
administration, efficacy , and safety  outcomes.  Descriptive summaries of discrete data will 
present the number of patients and the incidence as a frequency  and as a percentage.  Descriptive 
summaries of continuous data will present the g roup mean, standard deviation, median, 
minimum, maximum, and sample size.  
For regulatory  reporting purposes, there are two time points for the analy ses:  (1) the primary  
analy sis [ADDRESS_451377] patient has been enrolled, and (2) the final analy sis after all 
patients have completed the study .  A separate and detailed statistical analy sis plan (SAP) 
developed prior to primary  analy sis will supersede analy ses specified in the protocol.  Deviations 
from the SAP will be noted in the final study  report .  
Primary  Endpoint: The primary  endpoint in each arm of this trial is overall response rate.  
Overall response will be defined as a CI, PR, or CR (for Arms A, B, C, E, and F) according to the 
IWG-MRT consensus criteria for MF, or as a HI , PR or CR ( for Arm G) according to the I WG 
consensus criteria for MDS, or the achievement of <5% peripheral blood and bone marrow blast 
% that lasts for at least two months (for Arm D).
16.1. Statistical Design (To Be Evaluated Independently in Each Arm )
In a phase I I study  conducted at May o Clinic including 27 my elofibrosis patients treated with 
single agent Lenalidomide, 37% of patients responded in terms of anemia or splenomegaly .In a 
similar study  conducted at M.D. Anderson Cancer Center, a response rate of 24% in terms o f 
anemia or splenomegaly  was seen in 41 my elofibrosis patients also treated with single agent 
lenalidomide ( Tefferi et al. 2006). A response rate similar to or better than L enalidomide would 
be of interest for my
elofibros is patients treated with single agent I metelstat. Although this study 
also includes response in terms of platelets or ANC, we would expect the majority  of these 
patients to also have a response in terms of anemia or splenomegaly .In addition, we would 
expect patients with MDS/MPN or MDS with spliceosome mutations or ring sideroblasts to 
show similar outcomes to my elofibrosis.  Therefore, an overall response rate of 30% would be 
considered early  evidence of promising activity , for Arms A, B , C, E, F, and G .For Arm D, 20% 
response rate would be considered promising based on our single institutional experience of [ADDRESS_451378] phase MF ( Mesa et al . 2005 ); in the particular study , induction chemotherapy
resulted in 0% CR and short -lived reversal to chronic phase disease in 41%. 
Arm s A, B, C, D , and G :  The largest success proportion where the proposed treatment regimen 
would be considered ineffective in this population is 10%, and the smallest success proportion 
that would warrant subsequent studies with the proposed regimen in this patient population is 
30%. The following two
-stage Simon optimum design ( Simon 1989) uses [ADDRESS_451379] 
10%.
16.2111Stage 1: Enter 11 patients into each arm of the study (i.e. 11 patients each in Arms A, B, 
C
, D, and G ). If [ADDRESS_451380] 2, we will proceed to Stage 2 .
Stage 2: Enter an additional [ADDRESS_451381] 26 evaluable patients, we may  recommend further testing of 
this regimen in subsequent studies in this population.
Power and Significance Level : Assuming that the number of successes is binomially  distributed, 
with a significance level of 9%, the probability  of declaring that the regimen warrants further 
studies (i.e., statistical power) under various success proportions and the probability  of stoppi[INVESTIGATOR_362210] a function of the true success proportion as shown 
in the table below.
If the true succe ss proportion is… 0.10 0.15 0.20 0.25 0.30
Then the probability of declaring that 
the regimen is promising and warrants 
further study is…0.[ADDRESS_451382] stage is…0.[ADDRESS_451383] a formal statistical design, the reporting of results in this 
group will be primarily descriptive in nature.
Arms E and F :  The largest success proportion where the proposed treatment re gimen would be 
considered ineffective in this population is 10%, and the smallest success proportion that would 
warrant subsequent studies with the proposed regimen in this patient population is 30%.  The 
Protocol CP14B019, Amendment [ADDRESS_451384] 10%.
Final Decision Rule:  I f [ADDRESS_451385] 25 evaluable patients, we may  recommend further testing of this regimen in 
subsequent studies in this population.
Power and Significance Level : Assuming that the number of successes is bin omially  distributed, 
with a significance level of 10%, the probability  of declaring that the regimen warrants further 
studies (i.e., statistical power) under various success proportions can be tabulated as a function of 
the true success proportion as shown in the table below.
If the true success proportion is… 0.10 0.15 0.20 0.25 0.30
Then the probability of declaring that 
the regimen is promising and warrants 
further study is…0.10 0.32 0.58 0.79 0.91
Over Accrual: I f more than the target number of patie nts are accrued, the additional patients will 
not be used to evaluate the stoppi[INVESTIGATOR_362211]. Analy ses 
involving over accrued patients are discussed in Section 16.6.
Sample Size :  As of Addendum 3, accrual to Arm C will be permanently  discontinued.  The 11 
patients slotted to enroll on Arm C will now be treated per the Arm A or Arm B dose schedule.  
A total of 34 patients will be accrued between Arms A, B, and C
.  Accrual will continue per 
protocol in Arm D and t hree additional arms (Arms E, F, andG) will be added.  A total of 26 
evaluable patients (Arms D and G) or 25 evaluable patients (Arms E and F) will be accrued in 
each of the remaining arms.  An additional 3 patients will be accrued in each arm to account for 
patients who need to be replaced.  Therefore, the maximum overall sample size across all arms of 
the study  is now 148 patients.
As of 22Jan2014 study  is closed to enrollment with a total of 80 patients enrolled.
Accrua l Rate and Study  Duration:  As of 22Jan2014, all arms have permanently  discontinued 
accrual .  The 11 patients slotted to enroll on Arm C will now be treated per the Arm A or Arm B 
dose schedule.  
Other considerations:  Adverse events, quality /duration of response, and patterns of treatment 
failure observed in this study , as well as scientific discoveries or changes in standard care will be 
taken into account in any  decision to terminate the study
16.2. Analysis Plan
For regulatory  reporting purposes, t he primary analy sis will commerce [ADDRESS_451386]
-phase MF (Arm D) and those with MDS/MPN or MDS (Arm G) 
will be performed and pre sented separately .
Protocol CP14B019, Amendment 13
Page 77of 9016.3. Primary Outcome Analyses (to be evaluated in each arm 
independently)
Definition:  The primary  endpoint in each arm of this trial is the overall response rate.  For Arms 
A, B, C, E, and F overall response is defined to be a CI , PR, or CR noted as the objective status 
according to the I WG-MRT consensus criteria for MF.  Response in Arm G is defined as HI , PR 
or CR according to the I WG criteria for MDS ( Cheson et al . 2006 ).  Response in Arm D is 
defined by  a durable (2 months or more) decrease in peripheral blood and bone marrow blast 
percentage to less than 5%. All patients meeting the eligibility  criteria who have signed a 
consent form and have begun treatment will be evaluable for overall response.
Estimati on:  The proportion of successes will be estimated in each arm by [CONTACT_362251]. Ninety -five percent Clopper -
Pearson exact binomial confidence intervals for the true success proportion will be ca lculated. 
16.4. Secondary Outcome Analyses (to Be Evaluated in Each Arm 
Independently )
16.4.1. Advers e Events
All eligible patients that have initiated treatment will be considered evaluable for assessing 
adverse event rate(s).  The maximum grade for each ty pe of adver se event will be recorded for 
each patient, and frequency  tables will be reviewed to determine patterns.  Additionally, the 
relationship of the adverse event(s) to the study  treatment will be taken into consideration.  
16.4.2. Spleen Response
Spleen response is d efined as either a minimum 50% reduction in palpable splenomegaly  of a 
spleen that is at least 10 cm at baseline or a spleen that is palpable at less than 10 cm but more 
than 5 cm at baseline becomes not palpable. Spleen size will be measured by  [CONTACT_26857] (palpable distance from the left costal margin) at baseline and as part of each 
response assessment. The proportion of patients achieving spleen response per the I MG-MRT 
criteria ( Section 11) will be calculated by  [CONTACT_362252] (estimated 
to be approximately  80% of patients).  Same method willbe applied to splenectomized patients
for assessment of hepatomegaly  response. Ninety -five percent Clopper -Pearson exact binomial 
confidence intervals for the true proportion of patients with spleen response will be calculated.
16.4.3. Transfusion -Independence
Transfusion dependency  is defined by  [CONTACT_362253] [ADDRESS_451387] month for a hemoglobin level of less than 85 g/L  that was not associated with clinically  
overt bleeding (see I WG-MRT criteria; Section 11). The proportion of patients achieving 
transfusion independence during the first [ADDRESS_451388] 
Protocol CP14B019, Amendment 13
Page 78of 90binomial confidence intervals for the true proportion of patients who become transfusion 
independent will be calculated. The s ame statistical method will be applied to anemia response 
for Arm s A, B, E and F per I WG-MRT for myelofibrosis ( Teffe ri et al. 2013) and ery throid 
response for Arm G per I WG response criteria for MDS ( Cheson et al. 2006 ).
16.4.4. Durability of Response
Durability  overall response will be estima ted using the Kaplan -Meier method. Approximate 95%
confidence intervals for median duration of response will be computed using the formula 
proposed by  [CONTACT_362254] .  The s ame method will be applied to hepatosplenic 
response and 
anemia response f or Arms A, B, E, F, and D anderythroid response for Arm G. 
16.5. Exploratory Outcomes (to Be Evaluated in Each Arm 
Independently )
Due to the small overall sample size , the results of the following analy ses will be considered 
exploratory  and hy pothesis -generati ng in nature.
16.5.1. Bone Marrow Histology and JAK2V617F Allele Burden
Bone marrow fibrosis and granulocy te JAK2V617F allele burden will be assessed for all patients 
at baseline and at the time of the response bone marrow examination for patients who achieve a 
CR, PR, or CI  for Arms A, B, C, E, and F, CR, PR, and HI  for Arm G and for patients achieving 
durable (2 months or more) decrease in peripheral blood and bone marrow blast to less than 5% 
for Arm D.  Bone marrow fibrosis grade will be evaluated by  a central review pathologist and the 
fibrosis grade will be confirmed by  [CONTACT_978] .The proportion of patients achieving reversal of bone 
marrow fibrosis to a lower grade will be assessed and reported descriptively .  JAK2V617F allele 
burden will be summarized descriptively  at each time point and changes over time will be 
evaluated.
16.5.2. Leukocytosis, Thrombocytosis , Peripheral Blood Blast and Immature Cell Count
The proportion of patients with baseline leukocy tosis, thrombocy tosis or increased peripheral 
blood blast or imma ture cell count, who achieve normalization or at least a 50% reduction in 
their counts will be calculated and reported descriptively
16.6. Over Accrual
If more than the target number of patients are accrued, the additional patients will be included in 
final endp
oint estimates and confidence intervals.
16.7. Data and Safety Monitoring
A safety  committee internal to Janssen Research & Development will review the safety  data after 
approximately  every  3months until all patients have terminated from the study .  The safety  
review committee will consist of a study  responsible phy sician, safety  physician and a 
Protocol CP14B019, Amendment 13
Page 79of 90biostatistician .  The findings of the safety  committee will be shared with the study  Investigator.  
The study  responsible phy sician orsafety  physician may convene a mee ting sooner should any  
concerns arise from review of data or from the I nvestigator .
In addition to the safety  committee , an independent hepatic safety  panel will review emergent 
relevant safety  data , if needed.  I f there is evidence that imetelstat is resp onsible for the 
occurrence of a life -threatening, irreversible, or fatal hepatotoxicity  a full investigation will be 
conducted on the data available for imetelstat treatment of patients with my elofibrosis.  The 
investigation may  include, but is not limited to, a benefit -risk analy sis with external adjudication 
by [CONTACT_362255] .  Trial modifications, including trial 
closure, will be considered based on the results of this investigation.
16.8. Adverse Event Stoppi[INVESTIGATOR_362212](to Be Evaluated in Each Arm 
Independently )
The stoppi[INVESTIGATOR_362213].  
We note that the Adverse Event Stoppi[INVESTIGATOR_362214] (1) the 
study  re-opening to ac crual or (2) at any  time during the conduct of the trial and in consideration 
of newly  acquired information regarding the adverse event profile of the treatment(s) under 
investigation.  The study  team may  choose to suspend accrual because of unexpected adv erse 
event profiles that have not crossed the specified rule below.
Accrual will be temporarily  suspended to this study  if at any  time we observe events considered 
at least possibly  related to study  treatment (i.e. an adverse event with attribute specified as  
“possible”, “probable”, or “definite”) that satisfy either of the following:
If [ADDRESS_451389] 10 treated patients experience Grade 4 non-hematological 
toxicities
If after the first [ADDRESS_451390] been treated, 30% of patients experience Grade 4
non-hematologic toxicities
We note that we will review Grade 4 and 5 adverse events deemed “unrelated” or “unlikely  to be 
related”, to verify  their attribution and to monitor the emergence of a previously  unrecognized 
treatment -related adverse eve nt.
At study  activation, this study  will have been registered within the “ClincialTrails.gov” web site. 
The Primary  and Secondary  Endpoints ( i.e.
, “Outcome Measures”) along with other required 
information for this study  will be reported on ClinicalTrials.g ov. 
16.9. Inclusion of Women and Minorities
This study  will be available to all eligible patients, regardless of race, gender, or ethnic origin.
There is no information currently  available regarding differential effects of this regimen in 
subsets defined by  [CONTACT_545], gender, or ethnicity , and there is no reason to expect such differences to 
Protocol CP14B019, Amendment [ADDRESS_451391] based on racial and gender groupi[INVESTIGATOR_14839], the sample size is not increased in order to provide 
additional power for subset analy ses.
The geographical region served by  [CONTACT_128776] a po pulation which includes approximately  3% 
minorities. Based on prior MCCC studies involving similar disease sites, we expect about 3% of 
patients will be classified as minorities by  [CONTACT_31961] 50% of patients will be women. 
Expected sizes of racial by  [CONTACT_362256] 18below.
Table 18: Expected Sizes o f Racial by [CONTACT_362257]/Gender
Females Males Unknown Total
Hispanic or Latino 1 1 0 2
Not Hispanic or Latino 73 73 0 146
Unknown 0 0 0 0
Ethnic Category: Total of all subjects 74 74 0 148
Racial Category
American Indian or Alaskan Native 0 0 0 0
Asian 0 0 0 0
Black or African American 2 2 0 4
Native Hawaiian or other Pacific Islander 0 0 0 0
White 72 72 0 144
More than one race 0 0 0 0
Unknown 0 0 0 0
Racial Category: Total of all subjects 74 74 0 148
Ethnic 
Categories:Hispanic or Latino –a person of Cuban, Mexican, Puerto Rico, South or Central American, or other 
Spanish culture or origin, regardless of race. The term “Spanish origin” can also be used in addition to 
“Hispanic or Latino.”
Not Hisp anic or Latino
Racial 
Categories:American Indian or Alaskan Native –a person having origins in any of the original peoples of North, 
Central, or South America, and who maintains tribal affiliations or community attachment.
Asian – a person having origins in any of the original peoples of the Far East, Southeast Asia, or the 
Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, 
the Philippi[INVESTIGATOR_31922], Thailand, and Vietnam. (Note: Individuals from the Philip pi[INVESTIGATOR_362215].) 
Black or African Am erican –a person having origins in any of the black racial groups of Africa. Terms 
such as “Haitian” or “Negro” can be used in addition to “B lack or African American.”
Native Hawaiian or other Pacific Islander –a person having origins in any of the original peoples of 
Hawaii, Guam, Samoa, or other Pacific Islands.
White –a person having origins in any of the original peoples of Europe, the Mi ddle East, or North 
Africa.
Protocol CP14B019, Amendment 13
Page 81of 9017. PATHOLOGY CONSIDERAT IONS/TISSUE BIOSPECI MENS
Central review of the bone marrow will be performed by  [INVESTIGATOR_124]. at the May o Clinic in 
[COMPANY_002]ster , MN . Fibrosis grading and other histology changes will be documented.  
17.1. Tissue and Biospecimen Submission
Table 19: Summary Table of Tissue Biospecimens for this Protocol
Type of Tissue 
Biospecimen to 
SubmitMandatory 
or OptionalWhen to 
Submit Reason for Submission
Initial Bone 
Marrow Biopsie sMandatory Patients who achieve a CR, PR, or 
CI in the core phase ( Cycles 1-9)1:  
Submit with the response bone 
marrow biopsy
Patients who do not achieve a CR, 
PR, or CI in the core phase (Cycles 
1-9):  Submit at the end of Cycle 9 
or at the time of earl y 
discontinuation if patient receives < 
9 cyclesCentral review to evaluate 
extent of marrow 
involvement by 
[CONTACT_362258] , bone marrow 
cellularity and percentage of 
blasts and ring sideroblasts
Response Bone 
Marrow Biopsies
in patients who 
achieve a CR, P R, 
or CI during the 
core phaseMandatory ≤30 days after response bone 
marrow biopsyCentral review to evaluate 
extent of marrow 
involvement by 
[CONTACT_362258] , bone marrow 
cellularity and percentage of 
blasts and ring sideroblasts
1During the core phase 9 cycles, PR, or CI by [CONTACT_42334] 9:  Submit at the end of Cycle [ADDRESS_451392]. :
8-10 unstained and charged slides (or tissue block) from each bone marrow biopsy
Bone Marrow Form foreach bone marrow being sub
mitted
Baseline andResponse Bone Marrow Biop syReport
Slides should be placed in appropriate slide container(s) and labeled with the protocol number, 
study  patient number, and pa tient initials.

Protocol CP14B019, Amendment [ADDRESS_451393] the completed Bone Marrow Form and accompany ing reports to the 
study  QAS for scanning and data entry  purposes to the following:
QAS for CP14B019 (formerly  MC1285)
[ADDRESS_451394] SW
NW Clinic 3 -24
[COMPANY_002]ster, MN [ZIP_CODE]
Phone:
Refer to Test Schedule (Section 4). Data will be collected using an electronic data capture
system (EDC) based upon pre -specified electronic case report forms (eCRFs) and completion 
guidelines (CCGs).

Protocol CP14B019, Amendment 13
Page 83of 9018. REFERENCE S
Antonioli E, Guglielmelli P, Poli G, et al. Influence of JAK2V617F allele burden on phenotype in essential 
thrombocythemia. Haematologica 2008;93(1):41 –8.
Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagoni st (GRN163) as a potential anticancer 
agent. Cancer Res 2003;63(14):3931 –9.
Baerlocher GM, Oppliger -Leibundgut, et al.  Imetelstat Rapi[INVESTIGATOR_362216] (ET) who are Refractory or Intolerant to Prior 
Therapy:  Preliminary Phase II Results . Blood (ASH Annual Meeting Abstracts) 2012 ;120: Abstract 179.
Bernard L, Belisle C, Mollica L, et al.  Telomere length is severely and similarly reduced in JAK2V617F -positiv e 
and –negative myeloproliferative neoplasms. Leukemia 2009;23:287 –91.
Castelo -Branco P, Zhang C, Lipman T, et al. Selective targeting of cancer stem cells by [CONTACT_300440]. 
Submitted to Nat Med 2010.
Cheson BD, Greenberg PL, Bennett JM, Low enberg B, Wijermans PW, Nimer SD, Pi[INVESTIGATOR_1946] A, Beran M, de Witte TM, 
Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for 
modification of the International Working Group (IWG) response criteria in myelodysplasia. B lood
2006;108(2):419 -25.
Dikmen ZG, Ozgurtas T, Gryaznov SM et al. Targeting critical steps of cancer metastasis and recurrence using 
telomerase template antagonists.  Biochem Biophys Acta 2009;1792 (4) 240 –7.
Ferraris AM, Mangerini R, Pujic N, et al.  Hig h telomerase activity in granulocytes from clonal polycythemia vera 
and essential thrombocythemia. Blood 2005a;105(5):2138 –40.
Ferraris AM, Pujic N, Mongerini R, et al. Clonal granulocytes in polycythemia vera and essential thrombocythaemia 
have shortened telomeres. Br J Haematology 2005b;130:391 –3.
Harley CB, Sherwood SW. Telomerase, checkpoints and cancer. Cancer Surv 1997;29:263 –284.
Harley CB.  Telomerase is not an oncogene. Oncogene 2002; 21:494 –502.
Harley CB. Telomerase and cancer therapeutics. Nat Re v 2008;8: 167 –79.
Herbert B -S, Gellert GC, Hochreiter A, Pongracz K, et al. Lipid modification of GRN163, an N3’ -P5’ thio -
phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005;24:5262 –8.
Hochreiter AE, Xiao H, Goldbl att EM, et al. Telomerase template antagonist GRN163L disrupts telomere 
maintenance, tumor growth, and metastasis of breast cancer.  Clin Cancer Res 2006;12:3184 –92.
International Conference on Harmonisation (ICH), Guideline for Good Clinical Practice (E6)
.
Joseph I, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell 
lines. Cancer Res 2010a;15;70(22):9494 –504.
Joseph I, et al. In vivo and in vitro inhibition of multiple types of cancer stem cells by [CONTACT_3433] e novel t elomerase inhibitor 
imetelstat. Minisymposium, AACR Special Conference, The Role of Telomeres and Telomerase in Cancer Research, 
February 27–March 2, 2010b, Ft Worth, TX.
Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prost ate tumor -initiating cells. Int J 
Cancer 2010a;127(2):321 –31.
Marian CO, Cho SK, McEllin BM, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma 
tumor -
initiating cells leading to decreased proliferation and tumor growth. Clin Can cer Res 2010b;16(1):154 –63.
McEachern MJ, Krauskopf A, Blackburn EH. Telomeres and their control. Annual Rev Genet 2000; 34:331 –58.
Protocol CP14B019, Amendment 13
Page 84of 90Rufer N, Brümmendorf TH, Kolvraa S, et al. Telomere fluorescence measurements in granulocytes and t lymphocyte 
subsets point to a high turnover of hematopoietic stem cells and memory t cells in early childhood. J Exp Med 
1999;190(2):157 –67.
Shammas MA, Koley J, Bertheau RC, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro 
and in vivo. Leukemia 2008;22(7 ):1410 –8.
Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33(5):787 –91.
Simon R. Optimal two -stage designs for phase II clinical trials. Controlled Clinical Trials 1989;10(1):1 -10.
Stewart SA, Bertuch AA. The role o f telomeres and telomerase in cancer research. Cancer Res 2010;70:7365 -7371.
Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol
2011;86(12):1017 -1026. Prepublished on 2011/11/17 as DOI 10.1002/ajh. [ZIP_CODE].
Tefferi A, Barosi G, Mesa RA, et al. IWG for Myelofibrosis Research and Treatment (IWG -MRT). International 
Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the 
IWG for Myelofibrosis Research and Treatment (IWG -MRT). Blood 2006;108(5):1497 -503.
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health 
Organization criteria and point -of-care diagnostic algorithms. Leukemia 2008 ;22(1):14 -22.
Terasaki Y, Okumura H, Ohtake S, Nakao S. Accelerated telomere length shortening in granulocytes: a diagnostic 
marker for myeloproliferative diseases. Exp Hematology 2002;30: 1399 –404.
The Commission of the European Communities, Commission Directive 2005/28/EC .
The European Parliament and the Council of the European Union, Directive 2001/20/EC.
Protocol CP14B019, Amendment 13
Page 85of 90APPENDIX A. DIPSS -PLUS RISK CATEGORIES IN MYELOFIBROSIS.
The Dynamic International Prognostic Scoring System (DIPSS)- plus prognostic model for primary myelofibrosis 
(PMF). TheDIPSS -plus prognostic model for PMF uses [ADDRESS_451395] survival: age >65 years, 
hemoglobin level <10 g/dL, leukocyte count >25 × 109/L, circulating blasts ≥ 1%, presence of constitutional 
symptoms, presence of unfavorable karyotype, platelet count <100 × 109/L, and the presence of red cell transfusion 
need. 
*Transfusion dependency is defined by a history of at least [ADDRESS_451396] month 
for a hemoglobin level of less than 85 g/L that was not associated with clinically overt bleeding.  Please note 
that a transfusion -dependent patient automatically has 2 risk factors because of transfusion need (1 risk point) 
and he moglobin level <10 g/dL (1 risk point). 
**Constitutional symptoms constitute weight loss >10% of baseline value in the year preceding diagnosis, 
unexplained fever, or excessive sweats persisting for >1 month.
***Unfavorable karyotype constitutes complex karyotype or sole or 2 abnormalities that include +8, −7/7q−, i(17q), 
inv(3), −5/5q− 12p−, or 11q23 rearrangement.
Protocol CP14B019, Amendment 13
Page 86of 90APPENDIX B. WORLD HEALTH ORGANIZ ATION (WHO) 
DIAGNOSTIC CRITERIA FOR POLYCYTHEMIA VER A, 
ESSENTIAL THROMBOCYT HEMIA AND PRIMARY 
MYELOFIBROSIS3
2008 WHO D iagnostic Criteria
Polycythemia Vera1Essential Thrombocythemia1Primary Myelofibrosis1
Major 
criteria1Hgb > 18.5 g/dL (men)
> 16.5 g/dL (w omen)
Or21 Platelet count ≥ 450 x 109/L 1 Megakaryocyte proliferation
and atypia***3accompanied 
by [CONTACT_362259]/or 
collagen fibrosis, or4
2Presence of JAK2V617F 
or JAK2 exon 12 
mutation2 Megakaryocyte proliferation 
with large and mature 
morphology.2 Not meeting WHO criteria 
for CML, PV, MDS, or other 
myeloid neoplasm
3 Not meeting WHO criteri a for 
CML, PV, PMF, MDS or 
other myeloid neoplasm3 Demonstration of 
JAK2V617F or other clonal 
marker
or 
no evidence of reactive 
marrow fibrosis4 Demonstration of JAK2V617F 
or other clonal marker
or 
no evidence of reactive 
thrombocytosis 
Minor 
criteria1BM trilineage 
myeloproliferation1 Leukoerythroblastosis
2Subnormal serum Epo 
level2 Increased serum LDH level
3EEC grow th 3 Anemia
4 Palpable splenomegaly
Key: BM, bone marrow ; Hgb, hemoglobin; Hct, hematocrit; Epo, erythropoieti n; EEC, endogenous erythroid 
colony; WHO, World Health Organization; CML, chronic myelogenous leukemia; PV, polycythemia vera; PMF, 
primary myelofibrosis; MDS, myelodysplastic syndromes; LDH, lactate dehydrogenase
1PV diagnosis requires meeting either bo th major criteria and one minor criterion orthe first major criterion and [ADDRESS_451397] > 99thpercentile o f reference range for age, sex, or altitude of residence orred cell mass > 25% 
above mean normal predicted  orHgb > 17 g/dL (men)/ > 15 g/dL (w omen) if associated with a sustained increase 
of 2 g/dL from baseline that can not be attributed to correctio n of iron deficiency
3Small to large megakaryocytes with aberrant nuclear/cytoplasmic ratio and hyperchromatic and irregularly folded 
nuclei and dense clustering.
4In the absence of reticulin fibrosis, the megakaryocyte changes must be accompanied by [CONTACT_362260], granulocytic proliferation and often decreased erythropoiesis (i.e. pre -fibrotic PMF).
Protocol CP14B019, Amendment 13
Page 87of 90APPENDIX C. INTERNATIONAL WORKIN G GROUP FOR 
MYELOPROLIFERATIVE N EOPLASMS RESEARCH 
AND TREATMENT (IWG -MRT) RECOMMENDED 
CRITERIA FOR POST -POLYCYTHEMIA VERA AND 
POST -ESSENTIAL THROMBOCYT HEMIA 
MYELOFIBROSIS
Criteria for post -polycythemia vera myelofibrosis
Required criteria:
  1 Documentation of a previous diagnosis of polycythemia vera as defined by [CONTACT_175546] 
  2 Bone marrow  fibrosis Grade 2 –3 (on 0 –3 scale) or Grade 3 –4 (on 0 –4 scale) (see footnote for details) 
Additional criteria (tw o are required):
  1 Anemia or sustained loss of requirement for phlebotomy in the absence of cytoreductive therapy
  2 A leukoerythroblastic peripheral blood pi[INVESTIGATOR_1103]
  3Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥ 5cm (distance of the tip 
of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly
  4Development of  ≥ 1 of th ree constitutional symptoms: >10% weight loss in 6 months, night sweats, 
unexplained fever (>37.5°C)
Criteria for post -essential thrombocythemia myelofibrosis
Required criteria:
  1 Documentation of a previous diagnosis of essential thrombocythe mia as defined by [CONTACT_14300] 
  2 Bone marrow  fibrosis Grade 2 –3 (on 0 –3 scale) or Grade 3 –4 (on 0 –4 scale) (see footnote for details)
Additional criteria (tw o are required):
  1 Anemia and a ≥ 2g/dL decrease from baseline hemoglobin level
  2 A leukoerythroblastic peripheral blood pi[INVESTIGATOR_1103]
  3Increasing splenomegaly defined as either an increase in palpable splenomegaly of  ≥ 5cm (distance of the 
tip of the spleen from the l eft costal margin) or the appearance of a newly palpable splenomegaly
  4 Increased lactate dehydrogenase
  5Development of  ≥ 1 of three constitutional symptoms: >10% weight loss in 6 months, night sweats, 
unexplained fever (>37.5°C)
Note: Grade 2 –3 according to the European classification:5diffuse, often coarse fiber network with no evidence of 
collagenization (negative trichrome stain) or diffuse, coarse fiber network with areas of collagenization (positive 
trichrome stain). Grade 3 –[ADDRESS_451398] classification:6diffuse and dense increase in reticulin with 
extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis or diffuse and 
dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with 
significant osteosclerosis.
Protocol CP14B019, Amendment 13
Page 88of 90APPENDIX D. PERFORMANCE STATUS S CALE
Grade Description
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light housework or office work
2 Ambulatory and capable of all self -care but unable to carry out any work activities.  Up and 
about > 50% of waking hours
3 Capable of only limited self -care, confined to a bed or chair > 50% of waking hours
4 Completely disabled.  Cannot carry on any self- care.  Totally confined to bed or chair
5 Dead
Protocol CP14B019, Amendment 13
Page 89of 90APPENDIX E. ANAPHYLAXIS PRECAUTI ONS
EQUIPMENT NEEDED
Tourniquet
Oxygen
Epi[INVESTIGATOR_33414], intra venous, and/or endotracheal use, as indicated per 
standard institutional practice
Antihistamines
Corticosteroids
Bronchodilators, vasopressors, etc.
Endotracheal tube and other resuscitation equipment
IV infusion solutions, tubing, catheters, etc.
PROCEDUR ES
In the event of a suspected anaphy lactic reaction during infusion, the following procedures 
should be performed:
1.Stop the infusion.
2. Apply  a tourniquet proximal to the injection site to slow sy stemic absorption.  Do not 
obstruct arterial flow in the limb .
3.Maintain an adequate airway  and monitor vital signs.
4.Administer antihistamines, epi[INVESTIGATOR_238], or other medications such as bronchodilators, 
vasopressors, corticosteroids, etc. to manage patient sy mptomatically , as required by  
[CONTACT_362261] b y the phy sician in charge.
5.Continue to observe the patient and document observations and manage sy mptomatically .